

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
7 March 2002 (07.03.2002)

PCT

(10) International Publication Number
WO 02/18938 A1

(51) International Patent Classification⁷: **G01N 33/50**,
33/566, C12Q 1/68

(DE). **QUAST, Karsten** [DE/DE]; Raiffeisenstrasse 35,
88433 Schemmerberg (DE). **WEITH, Andreas** [DE/DE];
Buchenweg 13, 88436 Eberhardzell (DE).

(21) International Application Number: **PCT/EP01/09727**

(22) International Filing Date: 23 August 2001 (23.08.2001)

(25) Filing Language: English

(26) Publication Language: English

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK,
SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA,
ZW.

(30) Priority Data:
0021484.1 1 September 2000 (01.09.2000) GB

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,
CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,
TG).

(71) Applicant (*for all designated States except US*):
BOEHRINGER INGELHEIM PHARMA KG
[DE/DE]; 55216 Ingelheim/Rhein (DE).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **JUNG, Birgit**
[DE/DE]; Muhlstrasse 23, 55270 Schwabenheim (DE).
KRAUT, Norbert [DE/DE]; Erlenweg 19, 88436 Eber-
hardzell (DE). **MÜLLER, Stefan** [DE/DE]; Thalkirchner
Str. 184, 81371 München (DE). **KISTLER, Barbara**
[DE/DE]; Rheinstrasse 4, 64319 Pfungstadt (DE). **SEI-
THER, Peter** [DE/DE]; Elsterweg 4, 88400 Risseß Halde

Published:

— with international search report

*For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*



WO 02/18938 A1

(54) Title: METHOD FOR IDENTIFYING SUBSTANCES WHICH POSITIVELY INFLUENCE INFLAMMATORY CONDI-
TIONS OF CHRONIC INFLAMMATORY AIRWAY DISEASES

(57) Abstract: The present invention relates to substances which modulate receptors involved in inflammatory processes and whose modulated functions positively influence inflammatory diseases.

Method For Identifying Substances Which Positively Influence Inflammatory Conditions Of Chronic Inflammatory Airway Diseases

Introduction

5

The present invention belongs to the field of modulation of inflammatory processes, in particular of inflammatory airway diseases, in which macrophages play an important role. The inflammatory processes can be modulated according to the invention by influencing the function of receptors on macrophages, which receptors
10 are identified to be involved in the inflammatory process.

Inflammatory processes involve a cascade of reactions. A wide variety of factors are involved in inflammatory processes leaving a single treatment to avoid said factors unsuccessful. This is in particular true for inflammatory processes of the airways, like
15 the chronic inflammatory airway diseases.

Chronic inflammatory airway diseases include Chronic Bronchitis and Chronic Obstructive Pulmonary Disease (COPD). For example, COPD is a complex disease encompassing symptoms of several disorders: chronic bronchitis which is
20 characterized by cough and mucus hypersecretion, small airway disease, including inflammation and peribronchial fibrosis, and emphysema. COPD is characterized by an accelerated and irreversible decline of lung function. The major risk factor for developing COPD is continuous cigarette smoking. Since only about 20% of all smokers are inflicted with COPD, a genetic predisposition is also likely to contribute
25 to the disease.

The initial events in the early onset of COPD are inflammatory, affecting small and large airways. An irritation caused by cigarette smoking attracts macrophages and neutrophils the number of which is increased in the sputum of smokers. Perpetual
30 smoking leads to an ongoing inflammatory response in the lung by releasing mediators from macrophages, neutrophils and epithelial cells that recruit inflammatory cells to sites of the injury. So far there is no therapy available to reverse the course of COPD. Smoking cessation may reduce the decline of lung function. Only a few drugs provide some relief for patients. Longlasting β 2-agonists and
35 anticholinergics are applied to achieve a transient bronchodilatation. A variety of antagonists for inflammatory events are under investigation like, LTB_4 -, IL-8-, $TNF\alpha$ -inhibitors.

Chronic inflammatory airway diseases can be attributed to activated inflammatory immune cells, e.g. macrophages. There is a need for modulating the function of macrophages in order to eliminate a basis for inflammatory processes.

5

Description Of The Invention

In the present invention it was found that macrophages involved in an inflammatory process, preferably in a chronic inflammatory airway disease, more preferably in chronic bronchitis or COPD, show a pattern of differentially expressed nucleic acid sequence and protein expression which differs from the pattern of gene expression
10 of macrophages from healthy donors or donors in an irritated status, which latter do contain macrophages in an activated status. Therefore, macrophages show different activation levels under different inflammatory conditions and it is shown in the present invention that macrophages in an hyperactive status are involved in an inflammatory process, preferably in a chronic inflammatory airway disease, more
15 preferably in chronic bronchitis or COPD. The present invention provides for the inhibition of the hyperactivation or the reduction of the hyperactive status of a macrophage by allowing the identification of substances which modulate receptors involved in the hyperactivation or maintaining the hyperactive status.

20 The invention is based on the identification of a differentially expressed nucleic acid sequence or protein which is involved in causing the induction and/or maintenance of the hyperactive status of macrophages involved in an inflammatory process, preferably in a chronic inflammatory airway disease, more preferably in chronic bronchitis or COPD. Such differentially expressed nucleic acid sequence or protein is
25 in the following named differentially expressed nucleic acid sequence or protein of the invention respectively. In particular, the present invention teaches a link between phenotypic changes in macrophages due to differentially expressed nucleic acid sequence and protein expression pattern and involvement of macrophages in inflammatory processes and, thus, provides a basis for a variety of applications. For
30 example, the present invention provides a method and a test system for determining the expression level of a macrophage protein or differentially expressed nucleic acid sequence of the invention and thereby provides e.g. for methods for diagnosis or monitoring of inflammatory processes with involvement of hyperactivated macrophages in mammalian, preferably human beings, especially such beings
35 suffering from an inflammatory process, preferably in a chronic inflammatory airway disease, more preferably in chronic bronchitis or COPD. The invention also relates to a method for identifying a substance by means of a differentially expressed nucleic acid sequence or protein of the invention processes, which substance modulates, i.e. acts as an inhibitor or activator on the said differentially expressed nucleic acid

sequence or protein of the invention and thereby positively influences chronic inflammatory processes by inhibition of the hyperactivation or reduction of the hyperactive status of macrophages, and thereby allows treatment of mammals, preferably human beings, suffering from a said disease. The invention also relates to
5 a method for selectively modulating such a differentially expressed nucleic acid sequence or protein of the invention in a macrophage comprising administering a substance determined to be a modulator of said protein or differentially expressed nucleic acid sequence. The present invention includes the use of said substances for treating beings in need of a treatment of an inflammatory process, preferably a
10 chronic inflammatory airway disease, more preferably chronic bronchitis or COPD.

For the present invention in a first step differentially expressed nucleic acid sequences and proteins are identified which have a different expression pattern in a hyperactivated macrophage compared to a macrophage which is not hyperactivated.
15 For the sake of conciseness this description deals particularly with investigation of macrophages involved in COPD, however, equivalent results may be observed with samples from patients suffering from other chronic inflammatory airway diseases, e.g. chronic bronchitis. The investigation of the different expression pattern leads to the identification of a series of differentially expressed nucleic acid sequences in
20 macrophages, differentially expressed in dependency on the activation status of a macrophage involved in an inflammatory process, as exemplified in the Examples hereinbelow.

Briefly, such a differentially expressed nucleic acid sequence is identified by
25 comparative expression profiling experiments using a cell or cellular extract from a hyperactivated macrophage, i.e. for example from the site of inflammation in a COPD and from the corresponding site of control being not suffering from said disease, however, suffering from an irritated condition like cigarette smoke exposure.

30 A differentially expressed nucleic acid sequence or protein of the invention can easily be detected by such a method because amongst the differentially expressed macrophage genes a class of differentially expressed nucleic acid sequences can be identified which encodes a class of macrophage surface receptors which is characterized in that it is expressed at a lower or higher level than the control level in
35 a macrophage which is not hyperactivated. Such a macrophage surface receptor of the invention is hereinafter named ILM receptor. However, the invention does not only concern a naturally occurring ILM receptor, but also includes within the meaning of ILM receptor a receptor which is functionally equivalent to, i.e. which shares the binding capacities and the cellular function with an ILM receptor.

An example for an ILM receptor according to the present invention is a FPRL-1 receptor type receptor including FPRL-1 receptor (SEQ ID NO. 2). The term "receptor type receptor" used in context with the present invention, e.g. FPRL-1
5 receptor type receptor, is a receptor which is "functionally equivalent" to, i.e. which shares the binding capacities and the cellular function with, the respective receptor, e.g. FPRL-1 receptor of Seq. ID NO. 2; the term also encompasses variants, mutants or fragments of a naturally occurring receptor, e.g. FPRL-1 receptor. or naturally occurring receptor type receptor, e.g. FPRL-1 receptor type receptor, which variants,
10 mutants or fragments are functionally equivalent to the receptor, e.g. FPRL-1 receptor.

Further examples for ILM receptors are HM74 receptor type receptor including HM74 receptor (SEQ ID NO. 21); AICL receptor type receptor including AICL receptor
15 (SEQ ID NO. 6)); ILT1 receptor type receptor including ILT1 receptor (SEQ ID NO. 12); SHPS-1 receptor type receptor including SHPS-1 receptor (SEQ ID NO. 4); KDEL receptor 1 type receptor including KDEL receptor 1 (SEQ ID NO. 8); and CSF-1 receptor type receptor including CSF-1 receptor (SEQ ID NO. 10). Preferred is the respective receptor shown in the sequence listing or a variant, mutant or fragment
20 thereof having the same function, even more preferred is the respective receptor shown in the sequence listing under SEQ ID NO. 21, 6, 12, 4, 8, 10. In even more preferred embodiments the receptors are encoded by the nucleic acid sequences having the SEQ ID NOs 20, 5, 11, 3, 7 or 9, respectively.

25 A preferred embodiment of an ILM receptor in context with the present invention is a FPRL-1 receptor type receptor. The term FPRL-1 receptor type receptor accordingly also encompasses variants, mutants or fragments, of naturally occurring FPRL-1 receptor or FPRL-1 receptor type receptors, which variants, mutants or fragments are functionally equivalent to the FPRL-1 receptor. An even more preferred
30 embodiment in context with the description of the embodiments of the present invention is the FPRL-1 receptor of Seq. ID NO. 2 or a variant, mutant or fragment thereof having the same function, even more preferred is the FPRL-1 receptor of Seq. ID NO 2. In a most preferred embodiment, the FPRL-1 receptor is encoded by the nucleic acid sequence shown in SEQ ID NO. 1.

35

According to the present invention, the function of an ILM receptor expressed at a lower level than the control level is preferably activated in order to inhibit hyperactivation or reduce a hyperactivated status of a macrophage, whereby the function of an ILM receptor which is expressed at a higher level than the control level

is preferably inhibited in order to inhibit hyperactivation or reduce a hyperactivated status of a macrophage. Function of a receptor in context with the present invention is any function of a receptor of the invention which is capable of influencing the inflammatory processes. For example, a receptor of the invention is mediating
5 inflammation in that it is activated by a ligand (every substance which has the capacity to bind to said receptor at least one of its domains exposed on the cell surface) and leads to a intracellular signal involved in inflammatory processes.

In one embodiment the present invention concerns a method for determining a
10 substance to be an activator or inhibitor of an ILM receptor characterized in that the receptor is deregulated preferably overexpressed or downregulated in a macrophage involved in a chronic inflammatory airway disease and which receptor plays a role in mediating inflammation. A method according to the invention comprises the application of a substance of interest to a test system which generates a measurable
15 read-out upon modulation of the ILM receptor or of an ILM receptor function. A test system useful for performing such method of the invention comprises a cell or a cell-free system. For example, in one embodiment according to the invention the system is designed in order to allow the testing of substances acting on the expression level of the differentially expressed nucleic acid sequence, in another embodiment the
20 system allows the testing of substances directly interacting with the receptor or interfering with the binding of the receptor with a natural or an artificial but appropriate ligand. The latter system comprises a receptor of the invention in a way that a substance which should be tested can physically contact said receptor and which direct interaction leads to a measurable read-out indicative for the change of
25 receptor function.

A method according to the invention comprising a cellular system can be, for example, a method in which a MonoMac6 or a THP-1 cell is used wherein said cell is stimulated with phorbol 12-myristate 13-acetate and with a substance selected from a group consisting of LPS and smoke.

30

The present invention also provides a test system for determining whether a substance is an activator or an inhibitor according to the invention of an ILM receptor function according to the invention, characterized in that the receptor is involved in a chronic inflammatory airway disease and which receptor plays a role in mediating
35 inflammation, comprising at least an ILM receptor or an expression vector capable of expressing an ILM receptor in a cell or a host cell transformed with an expression vector capable of expressing an ILM receptor.

For performing a method for determining whether a substance is an activator or an inhibitor of receptor function of the present invention cells as well as cell-free

systems can be used. Test systems for performing the method can be, for example, designed and built up by using elements and methods well known in the art. For example, cell-free systems may include, for example, cellular compartments or vesicles comprising a receptor of the invention. Suitable cellular systems include, for example, a suitable prokaryotic cell or eukaryotic cell, i.e. such comprising a respective receptor of the invention. A cell suitable for performing a said method of the invention may be obtained by recombinant techniques, i.e. after transformation or transfection with a vector suitable for expression of the desired receptor of the invention, or may be a cell line or a cell isolated from a natural source expressing the desired receptor of the invention. A test system according to the invention comprising a cellular system can also be, for example, a test system in which a MonoMac6 or a THP-1 cell is used wherein said cell is stimulated with phorbol 12-myristate 13-acetate and with a substance selected from a group consisting of LPS and smoke. A test system according to the invention may include a natural or artificial ligand of the receptor if desirable or necessary for testing whether a substance of interest is an inhibitor or activator of a receptor of the invention.

A test method according to the invention comprises measuring a read-out, i.e. a phenotypic change in the test system, for example, if a cellular system is used a phenotypic change of the cell. Such change may be a change in a naturally occurring or artificial response of the cell to receptor activation or inhibition, e.g. as detailed in the Examples hereinbelow.

A test method according to the invention can on the one hand be useful for high throughput testing suitable for determining whether a substance is an inhibitor or activator of the invention, but also e.g. for secondary testing or validation of a hit or lead substance identified in high throughput testing.

The present invention also concerns a substance identified in a method according to the invention to be an inhibitor or activator of a receptor of the invention. A substance of the present invention is any compound which is capable of activating or preferably inhibiting a function of a receptor according the invention. An example of a way to activate or inhibit a function of a receptor is by influencing the expression level of said receptor. Another example of a way to activate or inhibit a function of a receptor is to apply a substance directly binding the receptor and thereby activating or blocking functional domains of said receptor, which can be done reversibly or irreversibly, depending on the nature of the substance applied.

Accordingly, a substance useful for activating or inhibiting receptor function include substances acting on the expression of differentially expressed nucleic acid sequence, but also such acting on the receptor itself. Therefore, according to the invention the meaning of the term a substance of the invention includes but is not
5 limited to nucleic acid sequences coding for the gene of a receptor of the invention or a fragment or variant thereof and being capable of influencing the gene expression level, e.g. nucleic acid molecules suitable as antisense nucleic acid, ribozyme, or for triple helix formation. Another substance of the invention is e.g. an antibody or an organic or inorganic compound directly binding to or interfering with the binding of an
10 appropriate ligand with a receptor of the invention and thereby affecting its function.

In a further aspect, the present invention relates to a method for determining an expression level of an ILM receptor differentially expressed nucleic acid sequence or protein according to the invention comprising determining the level of said ILM
15 receptor in a macrophage according to the invention. Such a method can be used, for example, for testing whether a substance is capable of influencing differentially expressed nucleic acid sequence expression levels in a method outlined above for determining whether a substance is an activator or inhibitor. A method for determining an expression level of an ILM receptor differentially expressed nucleic
20 acid sequence or protein can, however, also be used for testing the activation status of a macrophage, e.g. for diagnostic purposes or for investigation of the success of treatment of a disease which is caused by the hyperactivated macrophage.

Accordingly, the invention also relates to a method for diagnosis of a chronic inflammatory disease or monitoring of such disease, e.g. monitoring success in
25 treating beings in need of treatment of such disease, comprising determining the level of the receptor expressed in a macrophage according to the invention. Said macrophage is preferably a mammalian, more preferably a human cell. Accordingly, macrophages of the present invention are preferably obtainable from the site of inflammation in a mammal and more preferably from a site of inflammation in a
30 human being.

A method for determining expression levels of a receptor according to the invention can depending on the purpose of determining the expression level be performed by known procedures such as measuring the concentration of respective RNA
35 transcripts via hybridization techniques or via reporter gene driven assays such as luciferase assays or by measuring the protein concentration of said receptor using respective antibodies to verify the identity of said protein.

The present invention relates to the use of a substance according to the invention for the treatment of a chronic inflammatory airways disease according to the invention. Another embodiment of the present invention relates to a pharmaceutical composition comprising at least one of the substances according to the invention
5 determined to be an activator or an inhibitor using the method for determining whether the substance is an activator or an inhibitor according to the invention characterized in that the respective receptor according to the invention is overexpressed in a macrophage according to the invention involved in a chronic inflammatory airway disease according to the invention. The composition may be
10 manufactured in a manner that is itself known, e.g. by means of conventional mixing, dissolving, granulating, dragee-making, levigating, powdering, emulsifying, encapsulating, entrapping or lyophilizing processes.

In order to use substances activating or inhibiting according to the invention as drugs
15 for treatment of chronic inflammatory airway diseases, the substances can be tested in animal models for example an animal suffering from an inflammatory airway disorder or a transgenic animal expressing a receptor according to the invention. Toxicity and therapeutic efficacy of a substance according to the invention can be determined by standard pharmaceutical procedures, which include conducting cell
20 culture and animal experiments to determine the IC_{50} , LD_{50} and ED_{50} . The data obtained are used for determining the animal or more preferred the human dose range, which will also depend on the dosage form (tablets, capsules, aerosol sprays ampules, etc.) and the administration route (for example transdermal, oral, buccal, nasal, enteral, parenteral, inhalative, intratracheal, or rectal).

25 A pharmaceutical composition containing a least one substance according to the invention as an active ingredient can be formulated in conventional manner. Methods for making such formulations can be found in manuals, e.g. "Remington Pharmaceutical Science". Examples for ingredients that are useful for formulating at
30 least one substance according to the present invention are also found in WO 99/18193, which is hereby incorporated by reference.

In a further aspect the invention teaches a method for treating a chronic inflammatory airway disease according to the invention which method comprises administering to
35 a being preferably to a human being in need of such treatment a suitable amount of a pharmaceutical composition comprising at least one substance determined to be an activator or inhibitor according to a method for determining whether a substance is an activator or an inhibitor according to the invention of an ILM receptor according to the invention characterized in that the receptor is overexpressed in a macrophage

according to the invention and plays a role in mediating inflammation involved in a chronic inflammatory airway disease according to the invention.

In an other embodiment the invention relates to a method for selectively modulating
5 ILM receptor concentration in a macrophage, comprising administering a substance determined to be an activator or inhibitor of a receptor according to the invention.

The following examples are meant to illustrate the present invention, however, shall not be construed as limitation. However, the Examples describe most preferred
10 embodiments of the invention.

Examples

Example 1: Comparative Expression Profiling and FPLR-1 Cloning

- 5 The following is an illustration of how comparative expression profiling can be performed in order to identify receptors according to the present invention.

1.1. Selection of Patients

- Three groups of subjects are studied: healthy non-smokers, healthy smokers and
10 patients with COPD.

- In order to assess lung function subjects have to perform spirometry. A simple calculation based on age and height is used to characterise the results. COPD subjects are included if their FEV₁ % predicted is <70%. Healthy smokers are age and smoking history matched with the COPD subjects but have normal lung function.
15 Healthy non-smokers have normal lung function and have never smoked. The latter group has a methacholine challenge to exclude asthma. This technique requires increasing doses of methacholine to be given to the subject, with spirometry between each dose. When the FEV₁ falls 20% the test is stopped and the PC₂₀ is calculated. This is the dose of methacholine causing a 20% fall in FEV₁ and we will require a
20 value of >32 as evidence of absence of asthma. All subjects have skin prick tests to common allergens and are required to have negative results. This excludes atopic individuals. The clinical history of the subjects is monitored and examined in order to exclude concomitant disease.

25 1.2. BAL (bronchoalveolar lavage) Procedure

- Subjects are sedated with midazolam prior to the BAL. Local anaesthetic spray is used to anaesthetize the back of the throat. A 7mm Olympus bronchoscope is used. The lavaged area is the right middle lobe. 250 ml of sterile saline is instilled and immediately aspirated. The resulting aspirate contains macrophages.

30

1.3. BAL Processing

- BAL is filtered through sterile gauze to remove debris. The cells are washed twice in HBSS, resuspended in 1ml HBSS (Hank's Balanced Salt Solution) and counted. The macrophages are spun to a pellet using 15 ml Falcon blue-cap polypropylen,
35 resuspended in Trizol reagent (Gibco BRL Life Technologies) at a concentration of 1 ml Trizol reagent per 10 million cells and then frozen at -70°C.

1.4. Differential Gene Expression Analysis

Total RNA is extracted from macrophage samples obtained according to Example 1.3. Cell suspensions in Trizol are homogenized through pipetting and incubated at room temperature for 5 minutes. 200 μ l chloroform per ml Trizol is added, the mixture
5 carefully mixed for 15 seconds and incubated for 3 more minutes at room temperature. The samples are spun at 10000g for 15 minutes at 4°C. The upper phase is transferred into a new reaction tube and the RNA is precipitated by adding 0.5 ml isopropanol per ml Trizol for 10 minutes at room temperature. Then, the precipitate is pelleted by using a microcentrifuge for 10 minutes at 4°C with 10000g,
10 the pellet is washed twice with 75% ethanol, air dried and resuspended in DEPC-H₂O.

An RNA cleanup with Qiagen RNeasy Total RNA isolation kit (Qiagen) is performed in order to improve the purity of the RNA. The purity of the RNA is determined by agarose gelelectrophoresis and the concentration is measured by UV absorption at
15 260 nm.

5 μ g of each RNA is used for cDNA synthesis. First and second strand synthesis are performed with the SuperScript Choice system (Gibco BRL Life Technologies). In a total volume of 11 μ l RNA and 1 μ l of 100 μ M T7-(dt)₂₄ primer, sequence shown in SEQ ID NO. 13, are heated up to 70°C for 10 minutes and then cooled down on ice
20 for 2 minutes. First strand buffer to a final concentration of 1x, DTT to a concentration of 10 mM and a dNTP mix to a final concentration of 0.5 mM are added to a total volume of 18 μ l. The reaction mix is incubated at 42°C for 2 minutes and 2 μ l of Superscript II reverse transcriptase (200 U/ μ l) are added. For second strand synthesis 130 μ l of a mix containing 1.15x second strand buffer, 230 μ M
25 dNTPs, 10 U E.coli DNA ligase (10U/ μ l), E.coli DNA polymerase (10 U/ μ l), RNase H (2U/ μ l) is added to the reaction of the first strand synthesis and carefully mixed with a pipette. Second strand synthesis is performed at 16°C for 2 hours, then 2 μ l of T4 DNA polymerase (5 U/ μ l) are added, incubated for 5 minutes at 16°C and the reaction is stopped by adding 10 μ l 0.5 M EDTA.

30 Prior to cRNA synthesis the double stranded cDNA is purified. The cDNA is mixed with an equal volume of phenol:chloroform:isoamylalcohol (25:24:1) and spun through the gel matrix of phase lock gels (Eppendorf) in a microcentrifuge in order to separate the cDNA from unbound nucleotides. The aqueous phase is precipitated with ammoniumacetate and ethanol. Subsequently, the cDNA is used for in vitro
35 transcription. cRNA synthesis is performed with the ENZO BioArray High Yield RNA Transcript Labeling Kit according to manufacturer's protocol (ENZO Diagnostics). Briefly, the cDNA is incubated with 1x HY reaction buffer, 1x biotin labeled ribonucleotides, 1x DTT, 1x RNase Inhibitor Mix and 1x T7 RNA Polymerase in a

total volume of 40 μ l for 5 hours at 37°C. Then, the reaction mix is purified via RNeasy columns (Qiagen), the cRNA precipitated with ammonium acetate and ethanol and finally resuspended in DEPC-treated water. The concentration is determined via UV spectrometry at 260 nm. The remaining cRNA is incubated with
5 1x fragmentation buffer (5x fragmentation buffer: 200 mM Tris acetate, pH 8.1, 500 mM KOAc, 150 mM MgOAc) at 94°C for 35 minutes.

For hybridization of the DNA chip 15 μ g of cRNA is used, mixed with 50 pM biotin-labeled control B2 oligonucleotide, sequence shown SEQ ID NO. 14, 1x cRNA cocktail, 0.1 mg/ml herring sperm DNA, 0.5 mg/ml acetylated BSA, 1x MES (2-[N-morpholino]-ethanesulfonic acid) hybridization buffer in a total volume of 300 μ l. The
10 hybridization mixture is heated up to 99°C for 5 minutes, cooled down to 45°C for 10 minutes and 200 μ l of the mix are used to fill the probe array. The hybridization is performed at 45°C at 60 rpm for 16 hours.

After the hybridization the hybridization mix on the chip is replaced by 300 μ l non-stringent wash buffer (100 mM MES, 100 mM NaCl, 0.01% Tween 20). The chip is
15 inserted into an Affymetrix Fluidics station and washing and staining is performed according to the EukGE-WS2 protocol. The staining solution per chip consists of 600 μ l 1x stain buffer (100 mM MES, 1 M NaCl, 0.05% Tween 20), 2 mg/ml BSA, 10 μ g/ml SAPE (streptavidin phycoerythrin) (Dianova), the antibody solution consists of
20 1x stain buffer, 2 mg/ml BSA, 0.1 mg/ml goat IgG, 3 μ g/ml biotinylated antibody. After the washing and staining procedure the chips are scanned on the HP Gene Array Scanner (Hewlett Packard).

Data Analysis is performed by pairwise comparisons between chips hybridized with RNA isolated from COPD smokers and chips hybridized with RNA isolated from
25 healthy smokers.

One of the different expressed nucleic acid sequences identified is coding for FPRL-1 (formyl peptide receptor like-1) receptor (also named LXA₄R, HM63, FPR2, FPRH2, FMLP-R-II, Lipoxin A4 receptor); see Seq ID NOs. 1 and 2. It belongs to the
30 chemoattractant peptide receptor family including receptors for fMLP (N-formyl-methionyl-leucyl-phenylalanine), IL-8 or C5a. These receptors show a seven-transmembrane helix motif and signal through heterotrimeric G-proteins. FPRL-1 receptor was identified as the high-affinity receptor for lipoxin A₄ (LXA₄) (Murphy et al. 1992).

35

Alveolar macrophages have been shown to produce lipoxins, which are synthesized by 15-lipoxygenase (Kim 1988). Lipoxin A₄ (LXA₄) stimulates chemotaxis, adherence and calcium release in monocytes. In neutrophils, though, LXA₄ inhibits chemotaxis and adhesion, and downregulates transmigration through epithelial cells (Maddox

and Serhan 1996). LXA_4 was found elevated in BALs from patients with asthma (Lee et al. 1990, Serhan 1999). In particular, it was found to cause a dose-dependent contraction of human bronchi (Christie et al. 1992). LXA_4 is considered to be a generic modulator of inflammation in the lung.

5

1.5. FPRL-1 receptor Overexpressed in COPD Macrophages

FPRL-1 receptor is consistently found upregulated (66.7%) in COPD smokers compared to healthy smokers. This is demonstrated by calculated "fold change" values from 42 pairwise comparisons and by average difference ("avg diff") values
 10 (Table 1, 2). Relative expression levels for non-smokers and healthy smokers are similar and elevated levels are restricted to patients with COPD. Therefore, COPD-specific effects cause the upregulation.

Table 1: Expression pattern for FPRL-1 receptor: fold change calculation for 42
 15 pairwise comparisons between COPD and healthy smokers. Only values higher than 2fold and lower than -2fold are considered as deregulated. Thus FPRL-1 receptor was 28 times upregulated and 14 times not regulated.

20	fold change	comparison	fold change	comparison	fold change	comparison
	2.7	39vs2	2.9	5vs2	3.3	1vs2
	4.6	39vs37	3.6	5vs37	5.5	1vs37
25	2	39vs43	1.4	5vs43	1.4	1vs43
	3.1	39vs56	3	5vs56	3.9	1vs56
30	4.1	39vs57	3.2	5vs57	5.3	1vs57
	2.9	39vs58	3	5vs58	3.6	1vs58
	2.2	39vs62	2.7	5vs62	2.7	1vs62
35	1.3	44vs2	2.7	6vs2	1.4	3vs2
	2.7	44vs37	4.1	6vs37	2.9	3vs37
40	-1.9	44vs43	1.1	6vs43	-1.7	3vs43
	1.5	44vs56	3.2	6vs56	1.7	3vs56
	2	44vs57	3.5	6vs57	2.3	3vs57
45	1.4	44vs58	2.9	6vs58	1.5	3vs58
	1.1	44vs62	2.2	6vs62	1.2	3vs62

Table 2: Expression levels of FPRL-1 receptor: "avg diff" values, a relative indicator of the intensity of the hybridisation signal on the chip, for each patient are listed; OS means obstructed smoker, HS healthy smoker, NS non-smoker

OS	avg diff	HS	avg diff	NS	avg diff
P 1	1276.7	P 2	490.4	P 48/49	248.2
P 3	553.6	P 37	52.1	P 50/52	565.7
P 5	1710.2	P 43	940	P 54/61	142.4
P 6	1046.9	P 56	327.1		
P 39	1025.2	P 57	238.7		
P 44	507.1	P 58	358.2		
		P62	469.6		

mean + std. dev.		1020.0 ± 452.5		410.9 ± 276.3		318.8 ± 220.3
Median		1036.1		327.1		248.2

5 P value for comparisons between COPD smokers and healthy smokers: 0.02

Chip data for FPRL-1 receptor are confirmed by TaqMan analysis (Perkin Elmer Applied Biosystems) for three COPD and two healthy smokers. Fold changes obtained by TaqMan very much resemble the data from the gene chips (Table 3).

10

Table 3: Upregulation of FPRL-1 receptor in COPD smokers determined by gene chips and TaqMan.

Fold change determination for FPRL-1 receptor by chip data in six comparisons between COPD smokers and healthy smokers is validated by analysis of the same samples by TaqMan and the relative upregulation is calculated with GAPDH as a housekeeping gene.

15

comparison	chip	TaqMan
1vs2	3.3	4.1
3vs2	1.4	2.2
39vs2	2.7	6.0

20

comparison	chip	TaqMan
1vs37	5.5	4.6
3vs37	2.9	2.5
39vs37	4.6	6.8

Another differentially expressed nucleic acid sequence identified codes for HM74 receptor, see SEQ ID NOs. 20 and 21, which belongs to the family of G-protein-coupled receptors. HM74 receptor was cloned from a human monocytic library (Nomura et al. 1993). To date, the ligand has not been identified. HM74 receptor is
 5 consistently found upregulated (54.8%) in COPD smokers compared to healthy smokers. This is demonstrated by calculated „fold change“ values (Table 5) from 42 pairwise comparisons and by „avg diff“ values (Table 6).

10 Table 5. Expression pattern for HM74 receptor: fold change calculation for 42 pairwise comparisons between COPD and healthy smokers. Only values higher than 2fold and lower than -2fold are considered as deregulated. Thus, HM74 receptor was 23 times upregulated and 17 times not regulated

15

	fold change	comparison	fold change	comparison	fold change	comparison
20	1.2	39vs2	4.5	5vs2	-1.2	1vs2
	4.7	39vs37	13.8	5vs37	2.8	1vs37
	-2.1	39vs43	2.5	5vs43	-2.2	1vs43
25	2.9	39vs56	8.6	5vs56	1.8	1vs56
	2.6	39vs57	8.9	5vs57	1.6	1vs57
30	2.6	39vs58	7.7	5vs58	1.6	1vs58
	2.4	39vs62	8.5	5vs62	1.5	1vs62
	2.8	44vs2	1	6vs2	-1.1	3vs2
35	8.8	44vs37	3.5	6vs37	3	3vs37
	1.5	44vs43	-1.7	6vs43	-2	3vs43
	5.5	44vs56	2.2	6vs56	1.9	3vs56
40	5.4	44vs57	2	6vs57	1.7	3vs57
	4.9	44vs58	1.9	6vs58	1.7	3vs58
45	5.2	44vs62	1.9	6vs62	1.7	3vs62

Table 6: Expression levels of HM74 receptor: "avg diff" values, a relative indicator of the intensity of the hybridisation signal on the chip, for each patient are listed; OS means obstructed smoker, HS healthy smoker, NS non-smoker

OS	avg diff	HS	avg diff	NS	avg diff
P 1	3233	P 2	3916.3	P 48/49	1690.7
P 3	3474.5	P 37	1154.5	P 50/52	4176.4
P 5	17671	P 43	5770.5	P 54/61	3504.8
P 6	4094.2	P 56	1860.2		
P 39	4201.3	P 57	1639.8		
P 44	11068.5	P 58	2080.2		
		P62	1721.6		

mean + std. dev.		7290.4 ± 5879.0		2591.9 ± 1652.5		3124.0 ± 1285.9
median		4147.8		2243.6		3504.8

5

Chip data for HM74 receptor are confirmed by TaqMan analysis for three COPD and two healthy smokers. Fold changes obtained by TaqMan very much resemble the data from the gene chips (Table 7).

10

Table 7: Upregulation of HM74 receptor in COPD smokers determined by gene chips and TaqMan.

Fold change determination for HM74 receptor by chip data in six comparisons between COPD smokers and healthy smokers is validated by analysis of the same samples by TaqMan and the relative upregulation is calculated with GAPDH as a housekeeping gene.

15

20

comparison	chip	TaqMan
1vs2	0.8	2.3
3vs2	0.9	0.8
39vs2	1.2	1.4

25

comparison	chip	TaqMan
1vs37	2.8	4.5
3vs37	3.0	1.4
39vs37	4.7	2.6

- Another differentially expressed nucleic acid sequence identified codes for AICL receptor (activation-induced C-type lectin), see SEQ ID NOs. 5 and 6., which is a type II membrane protein that recognizes and binds N-acetyl-galactosamin or – glucosamin moieties of plasma glycoproteins (Oda et al. 1988). It is expressed in lymphoid tissues and in hematopoietic cells as well as in NK and T cells. Its expression is induced during lymphocyte activation and after stimulation with PMA (Hamann et al. 1997). Since homologues of AICL receptor are involved in signal transmission in lymphocytes and in lymphocyte proliferation, it is tempting to assume that AICL receptor also participates in these processes (Hamann et al. 1993).
- AICL receptor is consistently found upregulated (66.7%) in COPD smokers compared to healthy smokers. This is demonstrated by calculated „fold change“ values (Table 8) from 42 pairwise comparisons and by „avg diff“ values (Table 9). The p value for the comparisons between COPD smokers and healthy smokers was 0.01.
- Table 8.** Expression pattern for AICL receptor: fold change calculation for 42 pairwise comparisons between COPD and healthy smokers. Only values higher than 2fold and lower than –2fold are considered as deregulated. Thus, AICL receptor was 28 times upregulated and 14 times not regulated

	fold change	comparison	fold change	comparison	fold change	comparison
20	1	39vs2	1.5	5vs2	-1.3	1vs2
	1.9	39vs37	2.8	5vs37	1.4	1vs37
25	-1.4	39vs43	2.4	5vs43	1.3	1vs43
	3.3	39vs56	5	5vs56	2.7	1vs56
30	6.9	39vs57	10	5vs57	5.3	1vs57
	3.1	39vs58	4.5	5vs58	2.3	1vs58
	3.3	39vs62	5.1	5vs62	2.7	1vs62
35	1.4	44vs2	-1.4	6vs2	-1.5	3vs2
	2.6	44vs37	1.2	6vs37	1.2	3vs37
40	2.3	44vs43	1.1	6vs43	1.1	3vs43
	4.2	44vs56	2.3	6vs56	2.3	3vs56
	9.6	44vs57	4.5	6vs57	4.5	3vs57
45	4.3	44vs58	2	6vs58	2	3vs58
	4.2	44vs62	2.3	6vs62	2.3	3vs62

Table 9: Expression levels of AICL receptor: "avg diff" values, a relative indicator of the intensity of the hybridisation signal on the chip, for each patient are listed; OS means obstructed smoker, HS healthy smoker, NS non-smoker

OS	avg diff	HS	avg diff	NS	avg diff
P 1	3415.3	P 2	4984.2	P 48/49	748.4
P 3	3412.9	P 37	2388.6	P 50/52	1726.5
P 5	6585.8	P 43	2722.5	P 54/61	1087.9
P 6	3444.7	P 56	1121.1		
P 39	4548.4	P 57	656.1		
P 44	6291.5	P 58	1476.0		
		P 62	1113.1		

mean + std. dev.		4622.4 ± 1474.3		2065.9 ± 1482.0		1187.5 ± 496.6
median		3996.6		1476.0		1087.9

5

Another differentially expressed nucleic acid sequence identified codes for ILT1 receptor (immunoglobulin-like transcript 1), see SEQ ID NOs. 11 and 12. ILT1 receptor belongs to the Ig superfamily receptors that is related to a subset of activating receptors similar to NK cell receptors for MHC class I molecules. ILT1 receptor is a 69 kDa glycosylated transmembrane receptor which is mainly expressed in lung and liver and in monocytes, granulocytes, macrophages, and dendritic cells (Samaridis and Colonna 1997). Upon crosslinking with antibodies ILT1 receptor interacts with the γ -chain of the Fc receptor (Fc ϵ R γ) (Nakajima et al. 1999)

15 ILT1 receptor is found consistently upregulated (59.5%) in COPD smokers compared to healthy smokers. This is demonstrated by „avg diff“ values (Table 10). The p value for the comparisons between COPD smokers and healthy smokers was 0.01.

Table 10: Expression levels of ILT1 receptor: "avg diff" values for each patient are listed as well as mean and median values for the three groups of subjects; OS means obstructed smoker, HS healthy smoker, NS non-smoker

OS	avgdiff	HS	avg diff	NS	avg diff
P 1	493.5	P 2	412.3	P 48/49	519.7
P 3	1186.0	P 37	457.2	P 50/52	645.0
P 5	1097.1	P 43	382.6	P 54/61	491.2
P 6	1387.6	P 56	180.5		
P 39	513.5	P 57	367.8		
P 44	1374.5	P 58	720.8		
		P 62	279.1		

mean + std. dev.		1008.8 ± 406.8		400.0 ± 168.6		552.0 ± 81.8
median		1141.6		382.6		519.7

5

Another differentially expressed nucleic acid sequence identified codes for SHPS-1 receptor (SIRP-alpha1, MYD1, MFR), see SEQ ID NOs. 3 and 4, which is known to be highly expressed in macrophages (Fujioka et al. 1996, Kharitononkov et al. 1997, Brooke et al. 1998). SHPS-1 receptor is a transmembrane glycoprotein belonging to immunoglobulin superfamily. It contains three extracellular Ig-like domains, a cytoplasmic tail with a potential tyrosine phosphorylation site and an immunoreceptor tyrosine-based inhibitory motif (ITIM). Tyrosine phosphorylation of SHPS-1 receptor occurs upon activation of receptor tyrosine kinases and leads to an association with SHP-1 (in macrophages) and SHP-2 (in non-hematopoietic cells) (Veillette et al. 1998). Moreover, other proteins have been found to associate with the intracytoplasmic domain of SHPS-1 receptor, and it is therefore tempting to assume that SHPS-1 receptor acts as a scaffolding protein.

SHPS-1 receptor is consistently found downregulated (73.8%) in COPD smokers compared to healthy smokers. This is demonstrated by calculated „fold change“ values (Table 11) from 42 pairwise comparisons and by „avg diff“ values (Table 12). The p value for the comparisons between COPD smokers and healthy smokers is 0.005.

25

Table 11. Expression pattern for SHPS-1 receptor: fold change calculation for 42 pairwise comparisons between COPD and healthy smokers. Only values higher than 2fold and lower than -2fold are considered as deregulated. Thus, SHPS-1 receptor is 29 times downregulated and 13 times not regulated

5						
	fold change	comparison	fold change	comparison	fold change	comparison
10	-1.3	39vs2	-3.4	5vs2	1.3	1vs2
	-2.8	39vs37	-6.8	5vs37	-1.7	1vs37
	-1.6	39vs43	-8.4	5vs43	-2.1	1vs43
15	-3.0	39vs56	-7.1	5vs56	-1.8	1vs56
	-5.6	39vs57	-13.2	5vs57	-3.4	1vs57
20	-5.4	39vs58	-12.6	5vs58	-3.2	1vs58
	-3.1	39vs62	-7.5	5vs62	-1.9	1vs62
	1.4	44vs2	-2.1	6vs2	-1.1	3vs2
25	-1.5	44vs37	-4.5	6vs37	-2.3	3vs37
	-1.8	44vs43	-5.6	6vs43	-2.9	3vs43
	-1.6	44vs56	-4.7	6vs56	-2.4	3vs56
30	-2.6	44vs57	-8.9	6vs57	-4.6	3vs57
	-2.5	44vs58	-8.5	6vs58	-4.4	3vs58
35	-1.7	44vs62	-4.9	6vs62	-2.5	3vs62

Table 12: Expression levels of SHPS-1 receptor: "avg diff" values for each patient are listed as well as mean and median values for the three groups of subjects; OS means obstructed smoker, HS healthy smoker, NS non-smoker

OS	avg diff	HS	avg diff	NS	avg diff
P 1	1837.8	P 2	1442.6	P 48/49	4979.9
P 3	1361.1	P 37	3115.0	P 50/52	1120.5
P 5	291.1	P 43	3897.3	P 54/61	2090.6
P 6	696.3	P 56	3280.8		
P 39	1105.4	P 57	6220.7		
P 44	2466.0	P 58	5928.9		
		P 62	3431.7		

mean + std. dev.		1293.0 ± 783.9		3902.4 ± 1671.3		2730.3 ± 2007.7
median		1233.4		3431.7		2090.6

5

Another differentially expressed nucleic acid sequence identified codes for KDEL receptor 1, see SEQ ID NOs. 7 and 8, which is a receptor that has important functions in protein folding and assembly in the endoplasmic reticulum. It recognizes soluble proteins with the amino acid sequence K-D-E-L and retrieves these proteins after binding to the endoplasmic reticulum (Townsend et al. 1993). KDEL receptor 1 may be involved in the regulation of protein transport in the Golgi complex. Upon binding of a ligand the KDEL receptor dimerizes and interacts with ARF GAP (GTPase-activating protein for the ADP-ribosylation factor) (Aoe et al 1997).

15 It is consistently found downregulated (71.4%) in COPD smokers compared to healthy smokers. This is shown by „avg diff" values (Table 13). The p value for the comparisons between COPD smokers and healthy smokers is 0.003.

Table 13: Expression levels of KDEL receptor 1: "avg diff" values for each patient are listed as well as mean and median values for the three groups of subjects; OS means obstructed smoker, HS healthy smoker, NS non-smoker

OS	avg diff	HS	avg diff	NS	avg diff
P 1	877.6	P 2	930.6	P 48/49	1532.9
P 3	1227.2	P 37	2151.4	P 50/52	786.4
P 5	870.6	P 43	1628.6	P 54/61	1571.5
P 6	1188.6	P 56	2232.9		
P 39	1404.5	P 57	2295.1		
P 44	798.1	P 58	2364.1		
		P 62	2092.0		

mean + std. dev.		1061.1 ± 245.3		1956.4 ± 512.1		1296.9 ± 442.6
median		1033.1		2151.4		1532.9

5

Another differentially expressed nucleic acid sequence identified codes for the macrophage colony-stimulating factor-1 receptor precursor (CSF-1 receptor, c-fms); see SEQ ID NOs. 9 and 10. The CSF-1 receptor belongs to the subfamily of receptor tyrosine kinases. Activation of the CSF-1 receptor results in complex formation of multiple proteins, e.g. CSF-1 receptor, Shc, PI3K, Grb2, Cbl, SHP-1, Src. Moreover, ligand binding also triggers rapid tyrosine phosphorylation of a plethora of cytoplasmic proteins like Cbl, STAT3, STAT5a, STAT5b, p85PI3K, SHP-1, Vav and proteins involved in cytoskeletal organization (Yeung et al. 1998). CSF-1 receptor regulates survival, proliferation, differentiation and morphology of mononuclear phagocytes (Hampe et al. 1989).

15

CSF-1 receptor is consistently found downregulated (45.2%) in COPD smokers compared to healthy smokers. This is shown by „avg diff“ values (Table 14). The p value for the comparisons between COPD smokers and healthy smokers is 0.002.

Table 14: Expression levels of CSF-1 receptor: "avg diff" values for each patient are listed as well as mean and median values for the three groups of subjects; OS means obstructed smoker, HS healthy smoker, NS non-smoker

5

OS	avg diff	HS	avg diff	NS	avg diff
P 1	1136.0	P 2	2591.4	P 48/49	2967.7
P 3	2262.5	P 37	3070.6	P 50/52	2041.6
P 5	829.5	P 43	2799.2	P 54/61	2376.4
P 6	1720.3	P 56	3293.1		
P 39	1860.7	P 57	3703.4		
P 44	1334.1	P 58	1904.9		
		P 62	2144.5		
mean + std. dev.	1523.9 ± 522.7		2786.7 ± 633.2		2461.9 ± 468.9
median	1527.2		2799.2		2376.4

1.6. Use of TaqMan Analysis for Validation of DNA-Chip Data and Diagnosis

10 mRNA-expression profiles obtained by DNA-chips are validated by TaqMan analysis with the same RNA preparations. Moreover, the method is also applied to determine mRNA-levels for FPRL-1 receptor in cultured cell lines and in cells isolated from human beings in order to monitor the progress of the disease.

Total RNA isolated from U937-cells that were treated for 3 days with 10 nM retinoic acid is used in order to optimize of reaction conditions for determining the mRNA-levels of FPRL-1 receptor and setting standard curves for FPRL-1 receptor and GAPDH (glyceraldehyde-3-phosphate dehydrogenase) as a housekeeping gene. Quantification of FPRL-1 receptor is done with the following primers: Forward primer (FP) see SEQ ID NO. 17, Reverse primer (RP) see SEQ ID NO. 18 and TaqMan probe (TP) see SEQ ID NO.19 labeled with reporter dye FAM at the 5' end and quencher dye TAMRA at the 3' end. For determining mRNA-levels for GAPDH a predeveloped kit "TaqMan GAPDH Control Reagents" (P/N 402869) from Perkin Elmer Applied Biosystems is used. The GAPDH probe is labeled with JOE as the reporter dye and TAMRA as the quencher dye. RT-PCR reactions are performed with the "TaqMan EZ RT-PCR Core Reagents" (P/N N808-0236) kit from Perkin Elmer Applied Biosystems. Standard curves for FPRL-1 receptor and GAPDH are performed with increasing concentrations of RNA from U937 cells treated with 1 µM retinoic acid ranging from 0, 5, 10, 25, 50 to 100 ng per assay. Reaction mixes

contain 1x TaqMan EZ-buffer, 3 mM Mn(Oac)₂, 300 μM dATP, dCTP, dGTP, and 600 μM dUTP, 2.5 U rTth DNA polymerase, 0.25 U AmpErase UNG in a total volume of 25 μl. For analysis of FPRL-1 receptor reaction mixes include 300 nM of FP and RP and 100 nM of TP. The primer concentrations for determining GAPDH levels are 200 nM for each primer and 100 nM for the GAPDH Taqman probe. In order to determine mRNA levels for FPRL-1 receptor and GAPDH in human subjects and cell lines 16 to 50 ng RNA per reaction are used. All samples are run in triplicate. The reactions are performed with "MicroAmp Optical 96-well reaction plates" sealed with "MicroAmp Optical Caps" (Perkin Elmer Applied Biosystems) in an ABI PRISM 7700 Sequence Detection System (Perkin Elmer Applied Biosystems). The PCR conditions are 2 minutes at 50°C, 30 minutes at 60°C, 5 minutes at 95°C, followed by 40 cycles of 20 seconds at 94°C and 1 minute at 59°C. Data analysis is done either by determining the mRNA levels for FPRL-1 receptor and GAPDH according to the standard curves or by directly relating C_T values for FPRL-1 receptor to C_T values for GAPDH. The latter can be done for these genes since the efficiencies for both reactions are around 95%. The same method is used for investigating mRNA levels isolated from COPD patients in order to diagnose the disease or, after treatment of patients with their putative active drugs to monitor the success of the treatment. The other receptors mentioned in example 1.5 are investigated accordingly by using the respective appropriate primers.

1.7. Cell Systems

Human monocytic/macrophage cell lines HL-60, U937, THP-1, and MonoMac 6 are used as cellular model systems. Cells are grown in RPMI 1640 media containing 10% FCS supplemented with 100 U/ml penicillin, 100 μg/ml streptomycin, 2 mM glutamine, and 1x non-essential amino acids. The media for MonoMac6 cells also includes 5 ml/l OPI media supplement (Sigma). MonoMac6 cells are exclusively cultured in 24-well plates. Cells are maintained in a humidified atmosphere with 5% CO₂ at 37°C and tested regularly for contamination by mycoplasma. Differentiation is achieved by adding 10 nM PMA (phorbol 12 myristate-13 acetate) to the media.

1.8. Cloning of FPRL-1 receptor

FPRL-1 receptor is cloned from a total RNA extracted from U937 cells that were treated with 1 μM retinoic acid for three days. 5 μg RNA is reverse transcribed into cDNA with 5 ng oligo(dt)₁₈ primer, 1x first strand buffer, 10 mM DTT, 0.5 mM dNTPs and 2 U Superscript II (Gibco BRL Life Technologies) at 42°C for 50 minutes. Then, the reaction is terminated at 70°C for 15 minutes and the cDNA concentration is determined by UV-spectrophotometry. For amplification of FPRL-1 receptor 100 ng

of the cDNA and 10 pmol of sequence-specific primers for FPRL-1 receptor (forward primer attB1; see SEQ ID NO. 15 and reverse primer attB2 ; see SEQ ID NO. 16) are used for PCR. Reaction conditions are: 2 minutes of 94°C, 35 cycles with 30 seconds at 94°C, 30 seconds at 53°C, 90 seconds at 72°C, followed by 7 minutes at 72°C with Taq DNA-polymerase. The reaction mix is separated on a 2% agarose gel, a band of about 1000bp is cut out and purified with the QIAEX II extraction kit (Qiagen). The concentration of the purified band is determined and about 120 ng are incubated with 300 ng of pDONR201, the donor vector of the Gateway system (Gibco BRL Life Technologies), 1x BP clonase reaction buffer, BP clonase enzyme mix in a total volume of 20 µl for 60 minutes at 25°C. Then, reactions are incubated with 2 µl of proteinase K and incubated for 10 minutes at 37°C. The reaction mix is then electroporated into competent DB3.1 cells and plated on Kanamycin-containing plates. Clones are verified by sequencing. A clone, designated pDONR-HM63 carrying the nucleic acid sequence shown in SEQ ID No. 1 is used for further experiments.

The other receptors mentioned in example 1.5 are cloned using analogous methods.

1.9. Transfection of FPRL-1 receptor

The vector containing FPRL-1 receptor described under 1.8 is used to transfer the cDNA for FPRL-1 receptor to the expression vector pcDNA3.1(+)/attR that contains the "attR1" and "attR2" recombination sites of the Gateway cloning system (Gibco BRL Life Technologies) where FPRL-1 receptor is expressed under the control of the CMV promoter. 150 ng of the "entry vector" pDONR-HM63 is mixed with 150 ng of the "destination vector" pcDNA3.1(+)/attR, 4 µl of the LR Clonase enzyme mix, 4 µl LR Clonase reaction buffer, added up with TE (Tris/EDTA) to 20 µl and incubated at 25°C for 60 minutes. Then, 2 µl of proteinase K solution is added and incubated for 10 minutes at 37°C. 1 µl of the reaction mix is transformed into 50 µl DH5α by a heat-shock of 30 seconds at 42°C after incubating cells with DNA for 30 minutes on ice. After heat-shock of the cells 450 µl of S.O.C. is added and cells are incubated at 37°C for 60 minutes. Cells (100 µl) are plated on LB plates containing 100 µg/ml ampicillin and incubated over night.

A colony that contains pcDNA3.1(+)/attR with FPRL-1 receptor as an insert is designated pcDNA/FPRL1 and used for transfection studies.

Cell clones containing vectors obtained in 1.8 carrying nucleic acid sequences coding for the other receptors described 1.5 are prepared using analogous methods.

Example 2: Cellular Systems and Phenotypic Effects of FPRL-1 receptor

Analogous methods as described herein in example 2 for FPRL-1 receptor are also
5 performed using the other receptors described in 1.5.

2.1. Cell Systems

Human monocytic/macrophage cell lines HL-60, U937, THP-1, and MonoMac6 are used as cellular model systems. Cells are grown in RPMI 1640 media containing
10 10% FCS supplemented with 100 U/ml penicillin, 100 µg/ml streptomycin, 2 mM glutamine, and 1x non-essential amino acids. The media for MonoMac6 also includes 5 ml/l OPI media supplement (Sigma). MonoMac6 cells are exclusively cultured in 24-well plates. All cells are maintained in a humidified atmosphere with 5% CO₂ at 37°C and tested regularly for contamination by mycoplasma.
15 Differentiation is achieved by adding 10 nM PMA (phorbol 12 myristate-13 acetate) to the media.

Phenotypic effects of FPRL-1 receptor (2.2.-2.9.)

20 2.2. Ligand Binding Assay

300 ml cell culture is harvested with EDTA solution, the suspension is used to spin down the cells at 110-220 x g, resuspended in 10 mM Tris/HCl, pH 7.4, 2.5 mM CaCl₂, 1.2 mM MgCl₂, 40 µg/ml bacitracin, 4 µg/ml leupeptin, 4 µg/ml chymostatin, 10 µg/ml pefabloc, 2 µM phosphoramidon and 0,1 mg/ml bovine serum albumin
25 (BSA Fraktion V, BI Bioproducts) and diluted to 2 x 10⁶ cells/ml. 0.5 ml aliquots are incubated with 0.3 nM 3^H-lipoxin A4 (specific activity ~10 Ci/mmol) or in the presence of increasing concentrations of untritiated lipoxin A4 (3-300 nM) for 30 minutes at 4°C. The incubation is terminated by harvesting the cells by a Cell-Harvester (Skatron) with GF/B filters, washed three times with 3 ml chilled buffer
30 consisting of 50 mM Tris/HCl, 100 mM NaCl, 10 mM MgCl₂, pH 7.4 and the filter-pieces transferred in vials. 2 ml scintillation cocktail is added and the radioactivity determined with a scintillation counter (LKB). Non-specific binding is determined in the presence of 100 nM unlabeled lipoxin A4. A series of peptides and low molecular weight compounds, including the peptide ligand MMK-1 (Klein et al. 1998), is used in
35 a concentration range of 0.5 to 300 nM under the same reaction conditions in order to displace tritiated lipoxin A4.

The bound radioactivity (on the filter pieces) is estimated with a counter, the values are recorded on-line and fitted to a model. IC₅₀ values for any substance to block binding of 3^H-lipoxin A4 are calculated.

2.3. Ca^{2+} -Release Determined by FLIPR-Assay

FLIPR-assay (Fluorometric Imaging Plate Reader) with FPRL-1 receptor is performed with different CHO cell lines that constitutively express the G-protein α -subunit $\alpha 16$ or the chimeric G-proteins Gqi5 or Gqo5 (these are two $\text{G}\alpha(\text{q})$ chimeras harboring the last five residues of $\text{G}\alpha(\text{i})$ or $\text{G}\alpha(\text{o})$) and FPRL-1 receptor. The cell lines CHO/Galpha16 (CHO/Galpha16), CHO/GalphaGqi5 and CHO/GalphaGqo5 (Boehringer Ingelheim) that constitutively express $\text{G}\alpha 16$, Gqi5 or Gqo5 are transfected with the FPRL-1 receptor expression vector. The cell lines are cultured in Ham's F12 media (Bio Whittaker) with 10% FCS (fetal calf serum), 2 mM glutamine, 200 ng/ml hygromycin, 100 U/ml penicillin and 100 $\mu\text{g}/\text{ml}$ streptomycin in a humidified atmosphere with 5% CO_2 at 37°C. $3\text{--}7 \times 10^5$ cells are seeded in a 60 mm petri dish and grown over night. Cells that are grown to a confluency of 50–80% are used for transfection. 6 μl FuGene6 (Roche Biochemicals) is added to 100 μl of culture media without serum and equilibrated for 5 minutes at room temperature. Then, 2 μg of purified pcDNA/FPRL-1 receptor is added to the prediluted FuGene6 solution, gently mixed, and further incubated at room temperature for 15 minutes. The media is aspirated from the cells and 4 ml of fresh media is added to the cells. The FuGene6/DNA solution is added dropwise to the cells and distributed evenly by swirling of the media. After 48 hours the media is aspirated and replaced by Ham's F12 media, 10% FCS, 2 mM glutamine, 200 ng/ml hygromycin, 100 U/ml penicillin, 100 $\mu\text{g}/\text{ml}$ streptomycin, and 200 $\mu\text{g}/\text{ml}$ G418. During the following five days the media is replaced daily until dead cells and debris is washed out until single colonies of cells are visible. Single colonies are isolated by separation with cloning cylinders and releasing them from the surface by addition of 100 μl of 1x trypsin/EDTA. Cells are transferred from the cloning cylinders to 4 ml of media and plated in 6 well-plates. Single clones are expanded and the expression of FPRL-1 receptor in several clones is tested via ligand binding assay (2.2.). The cell clone denoted CHO/Galpha16/FPRL-1 receptor, CHO/GalphaGqi5/FPRL-1 receptor, or CHO/GalphaGqo5/FPRL-1 receptor with the highest expression of FPRL-1 receptor is used for measuring of intracytoplasmic Ca^{2+} via FLIPR (Molecular Devices). Cells (CHO/Galpha16/FPRL-1 receptor, CHO/GalphaGqi5/FPRL-1 receptor, or CHO/GalphaGqo5/FPRL-1 receptor) are seeded in 384-blackwell plates (Corning) with 2500–5000 cells per well in a volume of 40 μl and grown over night in a humidified atmosphere with 5% CO_2 at 37°C. As a negative control CHO/Galpha16, CHO/GalphaGqi5 or CHO/GalphaGqo5 cells are used. Then, 40 μl of a Fluo-4 (Molecular Probes) staining solution is added to each well in order to label the cells with Fluo-4 at a final concentration of 2 μM . The Fluo-4 staining solution is composed of 10.5 ml cell culture media described above, 420 μl Probenicid solution (1.42 g Probenicid (Sigma), 10 ml 1 M NaOH, 10 ml Hanks buffer), 42 μl Fluo-4 stock

solution (50 µg Fluo-4, 23 µl DMSO, 23 µl Pluronic F-127 (20% in DMSO) (Molecular Probes), and 420 µl 1M HEPES. After 45 minutes incubation in a humidified atmosphere with 5% CO₂ at 37°C wells are washed with a EMBLA-washer (4 wash steps, program 03) using 2000 ml Hanks buffer containing 20 ml Probenicid solution
5 as a wash solution and leaving 25 µl wash buffer in each well. Then FLIPR is set to 10000 counts for stained wells and a difference of 1:5 between unstained and stained wells. Then, 25 µl lipoxin A4 and a series of ligands, peptids, and low molecular weight compounds, including the peptide ligand MMK-1 is added to the wells in increasing concentrations (0.5 - 300 nM) diluted in Hanks' buffer/0.1% BSA.
10 Substances according to the invention are tested in increasing concentrations (0.5 - 300 nM) to compete with lipoxin A4 (50 nM) in order to determine their antagonistic potential. Fluorescence is recorded starting with the addition of the ligand every second for 60 seconds and every 5 seconds for a further 60 seconds.

15

2.4. Production and Release of Cytokines or Matrix Metalloproteases

Cells of monocytic/macrophage cell lines are treated with lipoxin A4 at cell densities between 2.5 and 5 x 10⁵ cells/ml. Cells are harvested after 0, 1, 3, 6, 12, 24, 48, and 72 hours, the supernatant frozen for further investigation, cells are washed with PBS,
20 and resuspended in 400 µl of RLT buffer (from Qiagen RNeasy Total RNA Isolation Kit) with 143 mM β-mercaptoethanol, the DNA sheared with a 20 g needle for at least 5 times and stored at -70°C.

Total RNAs are isolated with the Qiagen RNeasy Total RNA Isolation Kit (Qiagen) according to the manufacturer's protocol. Purified RNA is used for TaqMan analysis.

25 The expression levels of cytokines TNFα, IL-1β, IL-8, IL-6, and human matrix metalloproteases, MMP-1, MMP-7, MMP-9, MMP-12, are measured using appropriate primer sequences.

2.4.1. Detection of Secreted Cytokines

30 Proteins in the supernatants of the cultured and stimulated cells are precipitated by adding TCA (trichloroacetic acid) to a final concentration of 10%. Precipitates are washed twice with 80% ethanol and pellets are resuspended in 50 mM Tris/HCl, pH 7.4, 10 mM MgCl₂, 1 mM EDTA. Protein concentration is determined via the Bradford method and 50 µg of each sample are loaded on 12% SDS polyacrylamide gels.
35 Gels are blotted onto PVDF-membranes, blocked for 1 hour in 5% BSA in TBST, and incubated for 1 hour with commercially available antibodies against human TNFα (tumor necrosis factor α) IL-1β (interleukin-1β), IL-8 (interleukin 8), and IL-6 (interleukin 6). After washing with TBST blots are incubated with anti-human IgG conjugated to horseradish-peroxidase, washed again and developed with ECL

chemiluminescence kit (Amersham). Intensity of the bands are visualised with BioMax X-ray films (Kodak) and quantified by densitometry.

2.4.2. Detection and Activity of Secreted Matrix Metalloproteases

- 5 The procedure is identical to the one described in 2.4.1. Antibodies used for Western blotting are against human MMP-1, MMP-7, MMP-9, and MMP-12.

Protease activity is determined with a fluorescent substrate. Supernatants isolated from stimulated and unstimulated cells (described above) are incubated in a total
10 volume of 50 μ l with 1 μ M of the substrate (Dabcyl-Gaba-Pro-Gln-Gly-Leu-Glu (EDANS)-Ala-Lys-NH₂ (Novabiochem)) for 5 minutes at room temperature. Positive controls are performed with 125 ng purified MMP-12 per reaction. Protease activity is determined by fluorometry with an excitation at 320 nm and an emission at 405 nm.

- 15 In an alternative assay to determine proteolytic activity and cell migration a chemotaxis chamber is used. In the wells of the upper part of the chamber cells (10^5 cells per well) are plated on filters coated with an 8 μ m layer of Matrigel (Becton Dickinson). In the lower compartment chemoattractants like lipoxin A4 (100 nM), MCP-1 (monocyte chemotactic protein 1) (10 ng/ml) are added to the media. After
20 five days filters are removed, cells on the undersurface that have traversed the Matrigel are fixed with methanol, stained with the Diff-Quik staining kit (Dade Behring) and counted in three high power fields (400x) by light microscopy.

2.5. Chemotaxis Assay

- 25 In order to determine chemotaxis a 48 well chemotaxis (Boyden) chamber (Neuroprobe) is used. Cells are starved for 24 hours in RPMI media without FCS. Chemoattractants, (50 ng/ml IL-8, 10 ng/ml MCP-1, 10 nM lipoxin A4, 10 nM MMK-1 peptide (2.3.)) are diluted in RPMI media without FCS and 30 μ l is placed in the wells of the lower compartment. The upper compartment is separated from the lower
30 compartment by a polycarbonate filter (pore size 8 μ m). 50 μ l cell suspension (5×10^4) are placed in the well of the upper compartment. The chamber is incubated for 5 hours at 37°C in a humidified atmosphere with 5% CO₂. Then the filter is removed, cells on the upper side are scraped off, cells on the downside are fixed for 5 minutes in methanol and stained with the Diff-Quik staining set (Dade Behring). Migrated cells
35 are counted in three high-power fields (400x) by light microscopy.

2.6. Adherence Assay

Cells are harvested, washed in PBS and resuspended (4×10^6 /ml) in PBS and 1 μ M BCECF ((2'-7'-bis-(carboxethyl)-5(6')-carboxyfluorescein acetoxymethyl) ester,

Calbiochem) and incubated for 20 minutes at 37°C. Cells are washed in PBS and resuspended (3.3×10^6 /ml) in PBS containing 0.1% BSA. 3×10^5 cells (90 μ l) are added to each well of a 96-well flat bottom plate coated with laminin (Becton Dickinson) and allowed to settle for 10 minutes. 10 μ l of agonist (100 nM lipoxin A4 plus lipoxin A4 antagonist) are added and plates are incubated for 20 minutes at 37°C. Then, cells are washed with PBS containing 0.1% BSA and adherent cells are solubilized with 100 μ l of 0.025 M NaOH and 0.1% SDS. Quantification is performed by fluorescence measurement.

10 2.7. Phagocytosis

Cell suspensions (2.5×10^4 cells/ml) are seeded in 6-well plates with 5 ml of U937 or THP-1 or in 24-well plates with 2 ml of MonoMac6 and incubated for 1 hour at 37°C in a humidified atmosphere with 5% CO₂ in the presence of agonists (100 nM lipoxin A4, 50 nM MMK₂1 peptide (2.3.)) and low molecular weight compounds according to the invention in order to antagonize agonistic effects. 40 μ l of a dispersed suspension of heat-inactivated *Saccharomyces boulardii* (20 yeast/cell) are added to each well. Cells are incubated for three more hours, washed twice with PBS and cytocentrifuged. The cytospin preparations are stained with May-Grünwald-Giemsa and phagocytosed particles are counted by light microscopy.

20

25

Example 3: Cell Culture Model for Macrophages isolated from COPD patients

Analogous methods as describes here in example 3 for FPRL-1 receptor are also performed using receptors described in 1.5.

As a cell culture model for macrophages isolated from COPD patients we select the monocytic cell lines MonoMac6 and THP-1. In order to mimic a hyperactivated status of these cell lines, cells are treated with PMA. Cells are exposed to further stimuli that are to mimic a condition that is similar to the situation in COPD. These stimuli are exposure to smoke or to LPS.

35

**Expression of FPRL-1 after stimulation of MonoMac6 cells with PMA, smoke,
5 and LPS**

- MonoMac6 cells are cultivated in 24-well plates in RPMI 1640 media, supplemented with 10% FCS (low endotoxin), 2 mM glutamine, 1x non-essential amino acids, 200 U/ml penicillin, 200 µg/ml streptomycin, and 5 ml OPI media supplement (Sigma).
- 10 Cells are grown to a density of 600000 cells per well (2 ml media) and stimulated with 10 nM PMA (phorbol 12-myristate 13-acetate) (Sigma), or 20 ng/ml LPS (lipopolysaccharides from *Salmonella minnesota* Re595) (Sigma). For smoke exposure, cells are incubated in media enriched with smoke for 10 minutes at 37°C, 5% CO₂ at a density of 1 x 10⁶ cells/ml.
- 15 Enrichment of RPMI 1640 media with smoke is performed with the smoke of two cigarettes. The smoke of the cigarettes is pulled into a 50 ml syringe (about 20 volumes of a 50-ml syringe per cigarette) and then perfused into 100 ml of RPMI 1640 media without supplements. Afterwards, the pH of the smoke-enriched media is adjusted to 7.4 and the media is sterilized through a 0.2 µm filter before use. After
- 20 the exposure with smoke cells are washed at least twice with RPMI 1640 in order to remove residual smoke particles. Then cells are seeded in 24-well plates with 400000-600000 cells per well filled with 2 ml of fresh RPMI 1640 media including the supplements mentioned above.
- 25 THP-1 cells are grown in 75 cm² flasks in RPMI 1640 Glutamax supplemented with 10% FCS (low endotoxin), 200 U/ml penicillin, 200 µg/ml streptomycin. Cells are treated with 10 nM PMA for 48 hours at 37°C, 5% CO₂ in order to differentiate the cells to a macrophage-like cell type. Then, media is replaced by new PMA-free cultivation media with the addition of 20 ng/ml LPS.

30

Both cell types are cultivated at 37°C, 5% CO₂ in a humidified atmosphere and cells are harvested at various time points in order to monitor time-dependent effects. Cells are spun down and washed with PRS resuspended in 400 µl of RLT buffer (Qiagen

RNeasy Total RNA Isolation Kit) with 143 mM β -mercaptoethanol, the DNA is sheared with a 20 g needle for at least 5 times and stored at -70°C .

Total RNAs are isolated with the Qiagen RNeasy Total RNA Isolation Kit (Qiagen) according to the manufacturer's protocol. Purified RNA is digested with RNase-free
5 DNase (Qiagen) and used for TaqMan analysis.

TaqMan analysis

Taqman analysis is used to determine mRNA-levels for FPRL-1 in cell lines after
10 treatment with and without various stimuli at different time points. Total RNA isolated from U937 cells that were treated for 3 days with 10 nM retinoic acid is used in order to optimize of reaction conditions for determining the mRNA-levels of FPRL-1 and setting standard curves for FPRL-1 and GAPDH (glyceraldehyde-3-phosphate dehydrogenase) as a housekeeping gene. Quantification of FPRL-1 is done with the
15 following primers: Forward primer (rhHM63 668(-)FP, SEQ ID NO. 22), Reverse primer (hHM63 525(+))RP, SEQ ID NO. 23) and TaqMan probe (rhHM63 629(-)TP, SEQ ID NO. 24) labeled with reporter dye FAM at the 5' end and quencher dye TAMRA at the 3' end. The mRNA-levels for GAPDH are determined with a predeveloped kit for GAPDH "TaqMan GAPDH Control Reagents" (P/N 402869) from
20 PE Applied Biosystems. The GAPDH probe is labeled with JOE as the reporter dye and TAMRA as the quencher dye. RT-PCR reactions are performed with the "TaqMan EZ RT-PCR Core Reagents" (P/N N808-0236) kit from Perkin Elmer. Standard curves for FPRL-1 and GAPDH are performed with increasing concentrations of RNA from U937 cells treated with 1 μM retinoic acid ranging from
25 0, 5, 10, 25, 50 to 100 ng per assay. Reaction mixes contain 1x TaqMan EZ-buffer, 3 mM $\text{Mn}(\text{Oac})_2$, 300 μM dATP, dCTP, dGTP, and 600 μM dUTP, 2.5 U rTth DNA polymerase, 0.25 U AmpErase UNG in a total volume of 25 μl . For analysis of FPRL-1 reaction mixes include 300 nM of rhHM63 668(-)FP and hHM63 525(+))RP and 100 nM of rhHM63 629(-)TP. The primer concentrations for determining GAPDH levels
30 are 200 nM for each primer and 100 nM for the Taqman probe. In order to determine mRNA levels for FPRL-1 and GAPDH in human subjects and cell lines 16 to 50 ng RNA per reaction are used. All samples are run in triplicate. The reactions are performed with "MicroAmp Optical reaction plates" sealed with "MicroAmp

Optical Caps" (PE Applied Biosystems) in an ABI PRISM 7700 Sequence Detection System (PE Applied Biosystems). The PCR conditions are 2 minutes at 50°C, 30 minutes at 60°C, 5 minutes at 95°C, followed by 40 cycles of 20 seconds at 94°C and 1 minute at 59°C. Data analysis is done either by determining the mRNA levels for
 5 FPRL-1 and GAPDH according to the standard curves or by directly relating C_T values for FPRL-1 to C_T values for GAPDH. The latter procedure can be applied for these genes since the efficiencies for both reactions are in good agreement with each other (around 95%).

10

Tab. 1: Expression of FPRL-1 in MonoMac6 cells after stimulation with 10 nM PMA

t (h)	ng FPRL-1 mRNA/ ng GAPDH mRNA
0	0.00
1	0.00
3	0.00
12	0.00
24	0.00
48	0.43
72	0.01

Tab. 2: Expression of FPRL-1 in MonoMac6 cells after differentiation with 10 nM

15 PMA and stimulation with 20 ng/ml LPS

t (h)	ng FPRL-1 mRNA/ ng GAPDH mRNA
0	0.00
1	0.00
3	0.00
12	1.27
24	2.19
48	2.90
72	1.27

Tab. 3: Expression of FPRL-1 in MonoMac6 cells after differentiation with 10 nM

5 PMA and stimulation with smoke

t (h)	Fold induction of FPRL-1
0	1.00
1	0.02
3	0.14
6	4.44
12	9.90
25	9.35
48	8.73

Tab. 4: Expression of FPRL-1 in THP-1 cells after differentiation with PMA and stimulation with LPS

t (h)	Fold induction of FPRL-1
0	1.00
1	0.23
3	1.81
9	15.77
24	0.82
48	1.59

10

In order to examine the effects of ligands for FPRL-1, MonoMac6 cells are seeded at a density of 250000 cells/ml in 24-well plates (with 2 ml per well), grown for 24 hours at 37°C, 5% CO₂ in a humidified atmosphere before stimulation with 200 nM lipoxin

15 A4 (Biomol), W-peptide (1 µM) (synthesized by Metabion, Martinsried), and LPS (Sigma) as a positive control. Cells are harvested at different time points, and total

RNA is isolated as described above using the Qiagen RNeasy Total RNA Isolation Kit (Qiagen).

The sequence of the W-peptide (Baek et al. 1996, J. Biol. Chem 271, 8170-8175) is W-K-Y-M-V-m.

- 5 The RNA is used for Taqman analysis in order to monitor the expression of inflammatory markers like $\text{TNF}\alpha$, IL-8, and MMP-12.

Tab. 5: Expression of $\text{TNF}\alpha$ in MonoMac 6 cells after stimulation with lipoxin A4 and W-peptide

	<u>Fold Induction</u>	Fold Induction
t (h)	<u>Lipoxin A4 (200 nM)</u>	W-peptide (1 μM)
0	1.00	1.00
3	2.43	1.03

10

Tab. 6: Expression of IL-8 in MonoMac 6 cells after stimulation with lipoxin A4 and W-peptide

	<u>Fold Induction</u>	Fold Induction
t (h)	<u>Lipoxin A4 (200 nM)</u>	W-peptide (1 μM)
0	1.00	1.00
3	1.99	1.54

15

Tab. 7: Expression of MMP-12 in MonoMac 6 cells after stimulation with lipoxin A4 and W-peptide

	<u>Fold Induction</u>	Fold Induction
t (h)	<u>Lipoxin A4 (200 nM)</u>	W-peptide (1 μM)
0	1.00	1.00
3	1.42	1.51

Since an increased invasion of macrophages in peripheral airways of COPD patients can be observed, we tested the chemotactic ability of MonoMac6 cells which serve as a cell culture model for alveolar macrophages. Chemotaxis of MonoMac6 is
5 determined by administering different ligands for FPRL-1.

MonoMac6 cells are treated with PMA for 24-30 hours in order to induce an activation state of the cells. Cells are harvested, washed twice with RPMI 1640 without supplements, and seeded at a density of 500000 cells/well (24-well plate) in
10 the presence of 10 nM PMA. After 24-30 hours cells are released from the substratum by repeated rinsing with a pipet, spun down, counted and adjusted to a density of 1×10^6 cells/ml of RPMI 1640 media without supplements but in the presence of 10 nM PMA. Chemotaxis is performed in a 48-well chemotaxis chamber (Neuroprobe Inc.) and polycarbonate membranes with a pore size of 8 μ m
15 (Neuroprobe Inc.). The lower wells of the chamber are filled with 28 μ l of different concentrations of lipoxin A4, W-peptide, MCP-1 as a positive control, and RPMI 1640 media without supplements (including 10 nM PMA) as a negative control. The lower wells are covered with the polycarbonate membrane and the upper compartments of the chamber are filled with 50 μ l of the cell suspension (50000 cells per well). After 4
20 hours of migration at 37°C, 5% CO₂ the cells on the upper part of the membrane are scraped off and the cells attached at the lower part of the membrane are stained with the Diff Quik Staining Set (Dade Behring) according to the manufacturer's protocol. Stained cells are counted in 6 to 8 high power fields at a magnification of 250x with a light microscope. The migration index represents the fold increase in the number of
25 cells migrated in response to the chemoattractant over control medium.

Tab. 8: Migration of MonoMac6 cells in response to lipoxin A4, W-peptide, and MCP-1

Stimulus	Migration Index
MCP-1 (20 ng/ml)	2.59
Lipoxin A4 (1 μ M)	1.68
Lipoxin A4 (100 nM)	1.31
Lipoxin A4 (10 nM)	0.86

W-peptide (1 μ M)	2.46
W-peptide (100 nM)	1.23
W-peptide (10 nM)	0.95

The above examples as well as a cell of each of the above cell culture models are used for determining whether a substance is an inhibitor or an activator of an ILM-receptor of the invention which is deregulated in a macrophage according to the
5 invention by adding a substance to be tested and subsequent measuring of a respective above described effect.

Literature (FPRL-1 receptor, HM74 receptor):

- Kim, S.J. (1988). Biochem. Biophys. Res. Commun. 150, 870-876.
- Lee, T.H., Crea, A.E.G., Gant, V., Spur, B.W., Marron, B.E., Nicolaou, K.C., Reardon, E., Brezinski, M., and Serhan, C. (1990). Am. Rev. Respir. Dis. 141, 1453-1458.
- Bao, L., Gerard, N.P., Eddy, R.L., Shows, T., and Gerard, C. (1991). Genomics 13, 437-440.
- Christie, P.E., Spur, B.W., and Lee, T.H. (1992). Am Rev. Respir. Dis. 145, 1281-1284.
- Ye, R.D., Cavanagh, S.L., Quehenberger, O., Prossnitz, E.R., and Cochrane, C.G. (1992). Biochem. Biophys. Res. Commun. 184, 582-589.
- Perez, H.D., Holmes, R., Kelly, E., McClary, J., and Andrews, W.H. (1992). Gene, 118, 303-304.
- Murphy, P.M., Özcelik, T., Kenney, R.T., Tiffany, H.L., McDermott, D., and Francke, U. (1992). J. Biol. Chem. 267, 7637-7643.
- Nomura, H., Nielsen, B.W., and Matsushima, K. (1993). Internat. Immunol. 5, 1239-1249.
- Levy, B.D., Romano, M., Chapman, H.A., Reilly, J.J., Drazen, J., and Serhan, C.N. (1993). J. Clin. Invest. 92, 1572-1579.
- Durstin, M., Gao, J.-L., Tiffany, H.L., McDermott, D., and Murphy, P.M. (1994). Biochem. Biophys. Res. Commun. 201, 174-179.
- Maddox, J.F. and Serhan, C.N. (1996). J. Exp. Med. 183, 137-146.
- Maddox, J.F., Hachicha, M., Takano, T., Petasis, N.A., Fokin, V.V., and Serhan, C.N. (1997). J. Biol. Chem. 272, 6972-6978.
- Klein, C., Paul, J.I., Sauvé, K., Schmidt, M.M., Arcangeli, L., Ransom, J., Truelheart, J., Manfredi, J.P., Broach, J.R., and Murphy, A.J. (1998). Nature Biotech. 16, 1334-1337.
- Serhan, J.N. (1999). 133-149 in *Lipoxygenases and Their Metabolites*, ed. Nigam and Pace-Asciak, Plenum Press, New York.

30

Literature (AICL receptor):

- Oda, S., Sato, M., Toyoshima, S., and Osawa, T. (1988). J. Biochem. 104, 600-605.
- Hamann, J., Fiebig, H., and Strauss, M. (1993). J. Immunol. 150, 4920-4927.
- Hamann, J., Montgomery, K.T., Lau, S., Kucherlapati, R., and van Lier, R.A.W. (1997). Immunogenetics 45, 295-300.

35

Literature (ILT1 receptor):

- Samaridis, J., and Colonna, M. (1997). Eur. J. Immunol. 27, 660-665.

Nakajima, H., Samaridis, J., Angman, L., and Colonna, M. (1999). J. Immunol. 162, 5-8.

Literature (SHPS-1 receptor):

- 5 Fujioka, Y. et al. (1996). Mol. Cell. Biol. 16, 6887-6899.
Kharitonov, A., Chen, Z., Sures, I., Wang, H., Schilling, J., and Ullrich, A. (1997).
Nature 386, 181-186.
Brooke, G.P., Parsons, K.R., and Howard, C.J. (1998). Eur. J. Immunol. 28, 1-11.
Veillette, A., Thibadeau, E., and Latour, S. (1998). J. Biol. Chem. 273, 22719-
10 22728.

Literature (KDEL receptor 1):

- Townsley, F.M., Wilson, D.W., and Pelham, D.R. (1993). EMBO J. 12, 2821-2829.
Aoe, T., Cukierman, E., Lee, A., Cassel, D., Peters, P.J., and Hsu, V.W. (1997).
15 EMBO J. 16, 7305-7316.

Literature (CSF-1 receptor):

- Hampe, A., Shamoon, B.M., Gobet, M., Sherr, C.J., and Galibert, F. (1989).
Oncogene Res. 4, 9-17.
20 Yeung, Y.-G., Wang, Y., Einstein, D.B., Lee, P.S.W., and Stanley, E.R. (1998). J.
Biol. Chem. 273, 17128-17137.

Claims

- 1) A method for determining whether a substance is an activator or an inhibitor of an ILM receptor, comprising applying the substance to a test system which
5 generates a measurable read-out upon modulation of the ILM receptor or an ILM receptor function.
- 2) A method according to claim 1 in which said ILM receptor is a mammalian receptor.
- 10 3) A method according to claim 2 in which said ILM receptor is a human receptor.
- 4) A method according to claim 1 in which the analysis is performed using a cellular system.
- 15 5) A method according to claim 4 in which a MonoMac6 or a THP-1 cell is used wherein said cell is stimulated with phorbol 12-myristate 13-acetate and with a substance selected from a group consisting of LPS and smoke.
- 20 6) A method according to claim 1 in which the analysis is performed using a cell-free system.
- 7) A method according to claim 1 in which said receptor is a receptor selected from the group consisting of FPRL-1 receptor type receptor including FPRL-1
25 receptor (SEQ ID NO. 2); HM74 receptor type receptor including HM74 receptor (SEQ ID NO. 21); AICL receptor type receptor including AICL receptor (SEQ ID NO. 6)); ILT1 receptor type receptor including ILT1 receptor (SEQ ID NO. 12); SHPS receptor type receptor including SHPS-1 receptor (SEQ ID NO. 4); KDEL receptor 1 type receptor including KDEL receptor 1 (SEQ ID NO. 8); and CSF-1
30 receptor type receptor including CSF-1 receptor (SEQ ID NO. 10).
- 8) A method according to claim 1 in which said receptor is a FPRL-1 receptor type receptor.
- 35 9) A method according to claim 8 in which the FPRL-1 receptor type receptor of SEQ ID NO 2 is used or a variant, mutant, or fragment thereof having the same function.

- 10) A method for determining an expression level of an ILM receptor comprising determining the level of ILM receptor expressed in a macrophage.
- 11) A method according to claim 10 in which said macrophage is a mammalian cell.
- 5 12) A method according to claim 11 in which said macrophage is a human cell.
- 13) A method according to claim 12 in which the analysis is performed using a macrophage or a part thereof obtainable from the site of inflammation.
- 10 14) A method according to claim 13 in which the analysis is performed using a macrophage or a part thereof obtainable from the site of inflammation in a mammal.
- 15 15) A method according to claim 14 in which the analysis is performed using a macrophage or a part thereof obtainable from the site of inflammation in a human being.
- 20 16) A method according to claim 10 in which said receptor is a receptor selected from the group consisting of FPRL-1 receptor type receptor including FPRL-1 receptor (SEQ ID NO. 2); HM74 receptor type receptor including HM74 receptor (SEQ ID NO. 21); AICL receptor type receptor including AICL receptor (SEQ ID NO. 6); ILT1 receptor type receptor including ILT1 receptor (SEQ ID NO. 12); SHPS receptor type receptor including SHPS-1 receptor (SEQ ID NO. 4); KDEL receptor 1 type receptor including KDEL receptor 1 (SEQ ID NO. 8); and CSF-1 receptor type receptor including CSF-1 receptor (SEQ ID NO. 10).
- 25 17) A method according to claim 10 in which said receptor is a FPRL-1 receptor type receptor.
- 30 18) A method according to claim 17 in which the FPRL-1 receptor type receptor of SEQ ID NO 2 is used or a variant, mutant, or fragment thereof having the same function.
- 35 19) A method according to claim 10 for diagnosis or monitoring of a chronic inflammatory airway disease.

- 20) A method according to claim 19 in which the chronic inflammatory airway disease is selected from the group consisting of chronic bronchitis and COPD.
- 21) A method according to claim 19 in which the analysis is performed using a macrophage or a part thereof obtainable from the site of inflammation.
- 22) A method according to claim 21 in which the analysis is performed using a macrophage or a part thereof obtainable from the site of inflammation in a mammal.
- 23) A method according to claim 22 in which the analysis is performed using a macrophage or a part thereof obtainable from the site of inflammation in a human being.
- 24) A test system for determining whether a substance is an activator or an inhibitor of an ILM receptor function characterized in that the receptor is involved in a chronic inflammatory airway disease and which receptor plays a role in mediating inflammation, comprising at least
- a) an ILM receptor or
 - b) an expression vector capable of expressing an ILM receptor in a cell or
 - c) a host cell transformed with an expression vector capable of expressing an ILM receptor.
- 25) A test system according to claim 24 in which said receptor is a receptor selected from the group consisting of FPRL-1 receptor type receptor including FPRL-1 receptor (SEQ ID NO. 2); HM74 receptor type receptor including HM74 receptor (SEQ ID NO. 21); AICL receptor type receptor including AICL receptor (SEQ ID NO. 6)); ILT1 receptor type receptor including ILT1 receptor (SEQ ID NO. 12); SHPS receptor type receptor including SHPS-1 receptor (SEQ ID NO. 4); KDEL receptor 1 type receptor including KDEL receptor 1 (SEQ ID NO. 8); and CSF-1 receptor type receptor including CSF-1 receptor (SEQ ID NO. 10).
- 26) A test system according to claim 24 in which said receptor is a FPRL-1 receptor type receptor.

- 27) A test system according to claim 26 in which the FPRL-1 receptor type receptor of SEQ ID NO 2 is used or a variant, mutant, or fragment thereof having the same function.
- 5 28) A test system according to claim 27 comprising a cell expressing an ILM receptor.
- 29) A test system according to claim 28 in which a MonoMac6 or a THP-1 cell is used wherein said cell is stimulated with phorbol 12-myristate 13-acetate and
10 with a substance selected from a group consisting of LPS and smoke.
- 30) A substance determined to be an activator or inhibitor of an ILM receptor.
- 31) A substance according to claim 30 in which said receptor is a receptor selected
15 from the group consisting of FPRL-1 receptor type receptor including FPRL-1 receptor (SEQ ID NO. 2); HM74 receptor type receptor including HM74 receptor (SEQ ID NO. 21); AICL receptor type receptor including AICL receptor (SEQ ID NO. 6)); ILT1 receptor type receptor including ILT1 receptor (SEQ ID NO. 12); SHPS receptor type receptor including SHPS-1 receptor (SEQ ID NO. 4); KDEL
20 receptor 1 type receptor including KDEL receptor 1 (SEQ ID NO. 8); and CSF-1 receptor type receptor including CSF-1 receptor (SEQ ID NO. 10).
- 32) A substance according to claim 30 in which said receptor is a FPRL-1 receptor type receptor.
25
- 33) A substance according to claim 32 in which the FPRL-1 receptor type receptor of SEQ ID NO 2 is used or a variant, mutant, or fragment thereof having the same function.
- 30 34) A substance which is an activator or inhibitor of an ILM receptor for the treatment of a disease.
- 35) A substance according to claim 34 in which said receptor is a receptor selected from the group consisting of FPRL-1 receptor type receptor including FPRL-1
35 receptor (SEQ ID NO. 2); HM74 receptor type receptor including HM74 receptor (SEQ ID NO. 21); AICL receptor type receptor including AICL receptor (SEQ ID NO. 6)); ILT1 receptor type receptor including ILT1 receptor (SEQ ID NO. 12); SHPS receptor type receptor including SHPS-1 receptor (SEQ ID NO. 4); KDEL

receptor 1 type receptor including KDEL receptor 1 (SEQ ID NO. 8); and CSF-1 receptor type receptor including CSF-1 receptor (SEQ ID NO. 10).

- 5 36) A substance according to claim 34 in which said receptor is a FPRL-1 receptor type receptor.
- 37) A substance according to claim 36 in which the FPRL-1 receptor type receptor of SEQ ID NO 2 is used or a variant, mutant, or fragment thereof having the same function.
- 10 38) A substance according to claim 34 in which said disease is a chronic inflammatory airway disease.
- 39) A substance according to claim 38 in which said chronic inflammatory airway disease is selected from the group consisting of chronic bronchitis and COPD.
- 15 40) A pharmaceutical composition comprising at least one substance determined to be an activator or inhibitor of an ILM receptor.
- 20 41) A pharmaceutical composition according to claim 40 in which said receptor is a receptor selected from the group consisting of FPRL-1 receptor type receptor including FPRL-1 receptor (SEQ ID NO. 2); HM74 receptor type receptor including HM74 receptor (SEQ ID NO. 21); AICL receptor type receptor including AICL receptor (SEQ ID NO. 6)); ILT1 receptor type receptor including ILT1 receptor (SEQ ID NO. 12); SHPS receptor type receptor including SHPS-1 receptor (SEQ ID NO. 4); KDEL receptor 1 type receptor including KDEL receptor 1 (SEQ ID NO. 8); and CSF-1 receptor type receptor including CSF-1 receptor (SEQ ID NO. 10).
- 25 42) A pharmaceutical composition according to claim 40 in which said receptor is a FPRL-1 receptor type receptor.
- 30 43) A pharmaceutical composition according to claim 42 in which the FPRL-1 receptor type receptor of SEQ ID NO 2 is used or a variant, mutant, or fragment thereof having the same function.
- 35 44) Use of a substance determined to be an activator or inhibitor of an ILM receptor for preparing a pharmaceutical composition for treating a chronic inflammatory airway disease.

- 45) Use of a substance according to claim 44 in which the chronic inflammatory airway disease is selected from the group consisting of chronic bronchitis and COPD.
- 5
- 46) A use according to claim 44 in which said receptor is a receptor selected from the group consisting of FPRL-1 receptor type receptor including FPRL-1 receptor (SEQ ID NO. 2); HM74 receptor type receptor including HM74 receptor (SEQ ID NO. 21); AICL receptor type receptor including AICL receptor (SEQ ID NO. 6));
- 10
- ILT1 receptor type receptor including ILT1 receptor (SEQ ID NO. 12); SHPS receptor type receptor including SHPS-1 receptor (SEQ ID NO. 4); KDEL receptor 1 type receptor including KDEL receptor 1 (SEQ ID NO. 8); and CSF-1 receptor type receptor including CSF-1 receptor (SEQ ID NO. 10).
- 15
- 47) A use according to claim 44 in which said receptor is a FPRL-1 receptor type receptor.
- 48) A use according to claim 47 in which the FPRL-1 receptor type receptor of SEQ ID NO 2 is used or a variant, mutant, or fragment thereof having the same
- 20
- function.
- 49) A method for treating a chronic inflammatory airway disease which method comprises administering to a being in need of such treatment a suitable amount of a pharmaceutical composition comprising at least one substance determined
- 25
- to be an activator or inhibitor of an ILM receptor
- 50) A method according to claim 49 in which said receptor is a receptor selected from the group consisting of FPRL-1 receptor type receptor including FPRL-1 receptor (SEQ ID NO. 2); HM74 receptor type receptor including HM74 receptor (SEQ ID NO. 21); AICL receptor type receptor including AICL receptor (SEQ ID NO. 6));
- 30
- ILT1 receptor type receptor including ILT1 receptor (SEQ ID NO. 12); SHPS-1 receptor type receptor including SHPS receptor (SEQ ID NO. 4); KDEL receptor 1 type receptor including KDEL receptor 1 (SEQ ID NO. 8); and CSF-1 receptor type receptor including CSF-1 receptor (SEQ ID NO. 10).
- 35
- 51) A method according to claim 49 in which said receptor is a FPRL-1 receptor type receptor.

- 52) A method according to claim 51 in which the FPRL-1 receptor type receptor of SEQ ID NO 2 is used or a variant, mutant, or fragment thereof having the same function.
- 5 53) A method according to claim 49 for treating a mammal
- 54) A method according to claim 53 for treating a human being
- 55) A method according to claim 49 for treating a chronic inflammatory airway
10 disease selected from the group consisting of chronic bronchitis and COPD.
- 56) A method for selectively modulating an ILM receptor in a macrophage, comprising administering a substance determined to be an activator or inhibitor of an ILM receptor.
- 15 57) A method according to claim 56 in which the macrophage is involved in a chronic inflammatory airway disease
- 58) A method according to claim 57 in which the chronic inflammatory airway
20 disease is selected from the group consisting of chronic bronchitis and COPD
- 59) A method according to claim 56 in which said receptor is a receptor selected from the group consisting of FPRL-1 receptor type receptor including FPRL-1 receptor (SEQ ID NO. 2); HM74 receptor type receptor including HM74 receptor
25 (SEQ ID NO. 21); AICL receptor type receptor including AICL receptor (SEQ ID NO. 6)); ILT1 receptor type receptor including ILT1 receptor (SEQ ID NO. 12); SHPS-1 receptor type receptor including SHPS-1 receptor (SEQ ID NO. 4); KDEL receptor 1 type receptor including KDEL receptor 1 (SEQ ID NO. 8); and CSF-1 receptor type receptor including CSF-1 receptor (SEQ ID NO. 10).
- 30 60) A method according to claim 56 in which said receptor is a FPRL-1 receptor type receptor.
- 61) A method according to claim 60 in which the FPRL-1 receptor type receptor of
35 SEQ ID NO 2 is used or a variant, mutant, or fragment thereof having the same function.

SEQUENCE LISTING

<110> Boehringer Ingelheim Pharma KG

5 <120> Method for identifying substances which positively
influence inflammatory conditions of chronic
inflammatory airway diseases

<130> 082_00n

10

<140>

<141>

<150> UK 0021484.1

15 <151> 2000-09-01

<160> 24

<170> PatentIn Ver. 2.1

20

<210> 1

<211> 1910

<212> DNA

<213> Homo sapiens

25

<400> 1

gaaaaggagc ttagctgctg gtgctgctgg caagatggaa accaacttct ccactcctct 60
gaatgaatat gaagaagtgt cctatgagtc tgctggctac actgttctgc ggatcctccc 120
attggtggtg cttgggggtca cctttgtcct cggggtcctg ggcaatgggc ttgtgatctg 180
30 ggtggctgga ttccggatga caccgacagt caccaccatc tgttacctga acctggccct 240
ggctgacttt tctttcacgg ccacattacc attcctcatt gtctccatgg ccatgggaga 300
aaaatggcct tttggctggt tcctgtgtaa gttaattcac atcgtggtgg acatcaacct 360
ctttggaagt gtcttcttga ttggtttcat tgcaactggac cgctgcattt gtgtcctgca 420
tccagtctgg gccagaacc accgcactgt gactctggcc atgaaggatga tcgtcggacc 480
35 ttggattctt gctctagtcc ttaccttgcc agttttcctc tttttgacta cagtaactat 540
tccaaatggg gacacatact gtactttcaa ctttgcattc tgggggtggca cccctgagga 600
gaggctgaag gtggccatta ccatgctgac agccagaggg attatccggt ttgtcattgg 660
cttttagcttg ccgatgtcca ttgttgccat ctgctatggg ctcatcgag ccaagatcca 720
caaaaagggc atgattaaat ccagccgtcc cttacgggtc ctactgctg tgggtggcttc 780

tttcttcac tcgttggttc ctttcaact ggttgccctt ctgggcaccg tctggctcaa 840
 agagatgttg ttctatggca agtacaaaat cattgacatc ctggttaacc caacgagctc 900
 cctggccttc ttcaacagct gcctcaaccc catgctttac gtctttgttg gccaaagactt 960
 ccgagagaga ctgatccact ccctgccac cagtctggag agggccctgt ctgaggactc 1020
 5 agccccaact aatgacacgg ctgccaattc tgcttcacct cctgcagaga ctgagttaca 1080
 ggcaatgtga ggatggggtc agggatattt tgagttctgt tcatcctacc ctaatgccag 1140
 ttccagcttc atctaccctt gagtcatatt gaggcattca aggatgcaca gctcaagtat 1200
 ttattcagga aaaatgcttt tgtgtccctg atttggggct aagaaataga cagtcaggct 1260
 actaaaatat tagtgttatt ttttgttttt tgacttctgc ctataccctg gggttaagtgg 1320
 10 agttgggaaa tacaagaaga gaaagaccgg tggggatttg taagacttag atgagatagt 1380
 gcataataag gggaagactt taaagtataa agtaaaatgt ttgctgtagg ttttttatag 1440
 ctattaaaaa aatcagatt atggaagttt tcttctattt ttagtttgct aagagttttc 1500
 tgtttctttt tcttacatca tgagtggact ttgcatttta tcaaatgcat tttctacatg 1560
 tattaagatg gtcataattat tcttcttctt ttatgtaa at cattataaat aatgttcatt 1620
 15 aagttctgaa tgttaaacta ctcttgaatt cctggaataa accacactta gtcctgatgt 1680
 actttaataa tttatatctc acaggagttg gttagaattt ctgtgtttat gtttatatac 1740
 tgttatttca ctttttctac tatccttgct aagttttcat agaaaataag gaacaaagag 1800
 aaacttgtaa tgggtctctga aaaggaattg agaagtaatt cctctgattc tgttttctgg 1860
 tgttatatct ttattaaata ttcagaaaaa ttcaccagtg aaaaaaaaaa 1910

20

<210> 2

<211> 351

<212> PRT

25 <213> Homo sapiens

<400> 2

Met Glu Thr Asn Phe Ser Thr Pro Leu Asn Glu Tyr Glu Glu Val Ser

1

5

10

15

30

Tyr Glu Ser Ala Gly Tyr Thr Val Leu Arg Ile Leu Pro Leu Val Val

20

25

30

Leu Gly Val Thr Phe Val Leu Gly Val Leu Gly Asn Gly Leu Val Ile

35

35

40

45

Trp Val Ala Gly Phe Arg Met Thr Arg Thr Val Thr Thr Ile Cys Tyr

50

55

60

Leu Asn Leu Ala Leu Ala Asp Phe Ser Phe Thr Ala Thr Leu Pro Phe
 65 70 75 80

Leu Ile Val Ser Met Ala Met Gly Glu Lys Trp Pro Phe Gly Trp Phe
 5 85 90 95

Leu Cys Lys Leu Ile His Ile Val Val Asp Ile Asn Leu Phe Gly Ser
 100 105 110

10 Val Phe Leu Ile Gly Phe Ile Ala Leu Asp Arg Cys Ile Cys Val Leu
 115 120 125

His Pro Val Trp Ala Gln Asn His Arg Thr Val Ser Leu Ala Met Lys
 130 135 140

15 Val Ile Val Gly Pro Trp Ile Leu Ala Leu Val Leu Thr Leu Pro Val
 145 150 155 160

Phe Leu Phe Leu Thr Thr Val Thr Ile Pro Asn Gly Asp Thr Tyr Cys
 20 165 170 175

Thr Phe Asn Phe Ala Ser Trp Gly Gly Thr Pro Glu Glu Arg Leu Lys
 180 185 190

25 Val Ala Ile Thr Met Leu Thr Ala Arg Gly Ile Ile Arg Phe Val Ile
 195 200 205

Gly Phe Ser Leu Pro Met Ser Ile Val Ala Ile Cys Tyr Gly Leu Ile
 210 215 220

30 Ala Ala Lys Ile His Lys Lys Gly Met Ile Lys Ser Ser Arg Pro Leu
 225 230 235 240

Arg Val Leu Thr Ala Val Val Ala Ser Phe Phe Ile Cys Trp Phe Pro
 35 245 250 255

Phe Gln Leu Val Ala Leu Leu Gly Thr Val Trp Leu Lys Glu Met Leu
 260 265 270

Phe Tyr Gly Lys Tyr Lys Ile Ile Asp Ile Leu Val Asn Pro Thr Ser
 275 280 285

Ser Leu Ala Phe Phe Asn Ser Cys Leu Asn Pro Met Leu Tyr Val Phe
 5 290 295 300

Val Gly Gln Asp Phe Arg Glu Arg Leu Ile His Ser Leu Pro Thr Ser
 305 310 315 320

10 Leu Glu Arg Ala Leu Ser Glu Asp Ser Ala Pro Thr Asn Asp Thr Ala
 325 330 335

Ala Asn Ser Ala Ser Pro Pro Ala Glu Thr Glu Leu Gln Ala Met
 340 345 350

15

<210> 3
 <211> 2433
 <212> DNA
 20 <213> Homo sapiens

<400> 3
 cagccgcggc ccatggagcc cgccggcccg gcccccgcc gcctcgggcc gctgctctgc 60
 ctgtgctcg ccgcgtcctg cgccgtggtc ggagtgcccg gtgaggagga gctgcaggtg 120
 25 attcagcctg acaagtccgt atcagttgca gctggagagt cggccattct gcactgcact 180
 gtgacctccc tgatccctgt gggggccatc cagtgggtca gaggagctgg accagcccgg 240
 gaattaatct acaatcaaaa agaaggccac ttccccggg taacaactgt ttcagagtcc 300
 acaaagagag aaaacatgga cttttccatc agcatcagta acatcacccc agcagatgcc 360
 ggcacctact actgtgtgaa gttccggaaa gggagccctg acacggagtt taagtctgga 420
 30 gcaggcactg agctgtctgt gcgtgccaaa ccctctgccc ccgtggtatc gggccctgcg 480
 gcgagggcca cacctcagca cacagtgagc ttacactgcg agtcccacgg cttctcacc 540
 agagacatca ccctgaaatg gttcaaaaat gggaatgagc tctcagactt ccagaccaac 600
 gtggaccccg taggagagag cgtgtcctac agcatccaca gcacagcaa ggtggtgctg 660
 acccgcgagg acgttcactc tcaagtcac tgcgaggtgg ccacgtcac cttgcagggg 720
 35 gaccctcttc gtgggactgc caacttgtct gagaccatcc gagttccacc caccttgagg 780
 gtactcaac agcccgtag ggcagagaac caggtgaatg tcacctgcca ggtgaggaag 840
 ttctaccccc agagactaca gctgacctgg ttggagaatg gaaacgtgtc ccggacagaa 900
 acggcctcaa ccgttacaga gaacaaggat ggtacctaca actggatgag ctggctcctg 960
 gtgaatgtat ctgcccacag ggatgatgtg aagctcacct gccagtgga gcatgacggg 1020

cagccagcgg tcagcaaaag ccatgacctg aaggtctcag cccacccgaa ggagcagggc 1080
 tcaaataaccg ccgctgagaa cactggatct aatgaacgga acatctatat tgtggtgggt 1140
 gtggtgtgca ccttgctggg gccctactg atggcggccc tctacctcgt ccgaatcaga 1200
 cagaagaaag cccagggctc cacttcttct acaagggtgc atgagcccga gaagaatgcc 1260
 5 agagaaataa cacaggacac aaatgatatc acatatgcag acctgaacct gcccaagggg 1320
 aagaagcctg ctcccagggc tgcggagccc aacaaccaca cggagtatgc cagcattcag 1380
 accagcccgc agcccgctc ggaggacacc ctcacctatg ctgacctgga catggtccac 1440
 ctcaaccgga ccccaagca gccggccccc aagcctgagc cgtccttctc agagtacgcc 1500
 agcgtccagg tcccaggaa gtgaatggga ccgtggtttg ctctagcacc catctctacg 1560
 10 cgctttcttg tcccacaggg agccgccgtg atgagcacag ccaaccaggt tcccggaggg 1620
 ctggggcggg gcaggctctg ggaccaggg gccagggttg ctcttctctc cccacccctc 1680
 cttggtctc cagcacttcc tgggcagcca cgcccccctc ccccaacatt gccacacacc 1740
 tggaggctga cgttgcaaaa ccagccaggg aaccaacctg ggaagtggcc agaactgcct 1800
 ggggtccaag aactcttggt cctccgtcca tcacatgtg ggttttgaag accctcgact 1860
 15 gcctccccga tgctccgaag cctgatcttc cagggtgggg aggagaaaat cccacctccc 1920
 ctgacctcca ccacctccac caccaccacc accaccacca ccaccactac caccaccacc 1980
 caactggggc tagagtgggg aagatttccc cttagatca aactgcccct tccatggaaa 2040
 agctggaaaa aaactctgga acccatatcc aggcttggtg aggttgctgc caacagtcct 2100
 ggctcccc atccctaggc aaagagccat gagtctgga ggaggagagg accctccca 2160
 20 aaggactgga agcaaaacc tctgcttct tgggtccctc caagactccc tggggcccaa 2220
 ctgtgttgct ccaccggac ccatctctcc ctctagacc tgagcttgcc cctccagta 2280
 gcactaagca acatctcgct gtaagcgct gtaaattact gtgaaatgtg aaacgtgcaa 2340
 tcttgaaact gaggtgttag aaaacttgat ctgtggtgtt ttgtttgtt tttttctta 2400
 aaacaacagc aacgtgaaaa aaaaaaaaaa aaa 2433

25

<210> 4

<211> 503

30 <212> PRT

<213> Homo sapiens

<400> 4

Met Glu Pro Ala Gly Pro Ala Pro Gly Arg Leu Gly Pro Leu Leu Cys

35	1		5		10		15
----	---	--	---	--	----	--	----

Leu Leu Leu Ala Ala Ser Cys Ala Trp Ser Gly Val Ala Gly Glu Glu

20		25		30
----	--	----	--	----

Glu Leu Gln Val Ile Gln Pro Asp Lys Ser Val Ser Val Ala Ala Gly
35 40 45

Glu Ser Ala Ile Leu His Cys Thr Val Thr Ser Leu Ile Pro Val Gly
5 50 55 60

Pro Ile Gln Trp Phe Arg Gly Ala Gly Pro Ala Arg Glu Leu Ile Tyr
65 70 75 80

10 Asn Gln Lys Glu Gly His Phe Pro Arg Val Thr Thr Val Ser Glu Ser
85 90 95

Thr Lys Arg Glu Asn Met Asp Phe Ser Ile Ser Ile Ser Asn Ile Thr
100 105 110

15 Pro Ala Asp Ala Gly Thr Tyr Tyr Cys Val Lys Phe Arg Lys Gly Ser
115 120 125

Pro Asp Thr Glu Phe Lys Ser Gly Ala Gly Thr Glu Leu Ser Val Arg
20 130 135 140

Ala Lys Pro Ser Ala Pro Val Val Ser Gly Pro Ala Ala Arg Ala Thr
145 150 155 160

25 Pro Gln His Thr Val Ser Phe Thr Cys Glu Ser His Gly Phe Ser Pro
165 170 175

Arg Asp Ile Thr Leu Lys Trp Phe Lys Asn Gly Asn Glu Leu Ser Asp
180 185 190

30 Phe Gln Thr Asn Val Asp Pro Val Gly Glu Ser Val Ser Tyr Ser Ile
195 200 205

His Ser Thr Ala Lys Val Val Leu Thr Arg Glu Asp Val His Ser Gln
35 210 215 220

Val Ile Cys Glu Val Ala His Val Thr Leu Gln Gly Asp Pro Leu Arg
225 230 235 240

Gly Thr Ala Asn Leu Ser Glu Thr Ile Arg Val Pro Pro Thr Leu Glu
 245 250 255

Val Thr Gln Gln Pro Val Arg Ala Glu Asn Gln Val Asn Val Thr Cys
 5 260 265 270

Gln Val Arg Lys Phe Tyr Pro Gln Arg Leu Gln Leu Thr Trp Leu Glu
 275 280 285

10 Asn Gly Asn Val Ser Arg Thr Glu Thr Ala Ser Thr Val Thr Glu Asn
 290 295 300

Lys Asp Gly Thr Tyr Asn Trp Met Ser Trp Leu Leu Val Asn Val Ser
 305 310 315 320

15 Ala His Arg Asp Asp Val Lys Leu Thr Cys Gln Val Glu His Asp Gly
 325 330 335

Gln Pro Ala Val Ser Lys Ser His Asp Leu Lys Val Ser Ala His Pro
 20 340 345 350

Lys Glu Gln Gly Ser Asn Thr Ala Ala Glu Asn Thr Gly Ser Asn Glu
 355 360 365

25 Arg Asn Ile Tyr Ile Val Val Gly Val Val Cys Thr Leu Leu Val Ala
 370 375 380

Leu Leu Met Ala Ala Leu Tyr Leu Val Arg Ile Arg Gln Lys Lys Ala
 385 390 395 400

30 Gln Gly Ser Thr Ser Ser Thr Arg Leu His Glu Pro Glu Lys Asn Ala
 405 410 415

Arg Glu Ile Thr Gln Asp Thr Asn Asp Ile Thr Tyr Ala Asp Leu Asn
 35 420 425 430

Leu Pro Lys Gly Lys Lys Pro Ala Pro Gln Ala Ala Glu Pro Asn Asn
 435 440 445

His Thr Glu Tyr Ala Ser Ile Gln Thr Ser Pro Gln Pro Ala Ser Glu
 450 455 460

Asp Thr Leu Thr Tyr Ala Asp Leu Asp Met Val His Leu Asn Arg Thr
 5 465 470 475 480

Pro Lys Gln Pro Ala Pro Lys Pro Glu Pro Ser Phe Ser Glu Tyr Ala
 485 490 495

10 Ser Val Gln Val Pro Arg Lys
 500

<210> 5
 15 <211> 759
 <212> DNA
 <213> Homo sapiens

<400> 5

20 ctgtgctgta aaaacaagag taacattttt atattaaagt taaataaagt tacaactttg 60
 aagagagttt ctgcaagaca tgacacaaag ctgctagcag aaaatcaaaa cgctgattaa 120
 aagaagcacg gtatgatgac caaacataaa aagtgtttta taattgttgg tgttttaata 180
 acaactaata ttattactct gatagttaaa ctaactcgag attctcagag tttatgcccc 240
 tatgattgga ttggtttcca aaacaaatgc tattatttct ctaaagaaga aggagattgg 300
 25 aattcaagta aatacaactg ttccactcaa catgccgacc taactataat tgacaacata 360
 gaagaaatga attttcttag gcggtataaa tgcagttctg atcactggat tggactgaag 420
 atggcaaaaa atcgaacagg acaatgggta catggagcta catttaccaa atcgtttggc 480
 atgagaggga gtgaaggatg tgcctacctc agcgatgatg gtgcagcaac agctagatgt 540
 tacaccgaaa gaaaatggat ttgcaggaaa agaatacact aagttaatgt ctaagataat 600
 30 ggggaaaata gaaaataaca ttattaagtg taaaaccagc aaagtacttt ttaattaaa 660
 caaagttcga gttttgtacc tgtctgggta attctgctta cgtgtcaggc tacacataaa 720
 agccacttca aagattggca aaaaaaaaaa aaaaaaaaaa 759

35 <210> 6
 <211> 149
 <212> PRT
 <213> Homo sapiens

<400> 6

Met Met Thr Lys His Lys Lys Cys Phe Ile Ile Val Gly Val Leu Ile
 1 5 10 15
 Thr Thr Asn Ile Ile Thr Leu Ile Val Lys Leu Thr Arg Asp Ser Gln
 5 20 25 30

Ser Leu Cys Pro Tyr Asp Trp Ile Gly Phe Gln Asn Lys Cys Tyr Tyr
 35 40 45

10 Phe Ser Lys Glu Glu Gly Asp Trp Asn Ser Ser Lys Tyr Asn Cys Ser
 50 55 60

Thr Gln His Ala Asp Leu Thr Ile Ile Asp Asn Ile Glu Glu Met Asn
 65 70 75 80

15 Phe Leu Arg Arg Tyr Lys Cys Ser Ser Asp His Trp Ile Gly Leu Lys
 85 90 95

Met Ala Lys Asn Arg Thr Gly Gln Trp Val His Gly Ala Thr Phe Thr
 20 100 105 110

Lys Ser Phe Gly Met Arg Gly Ser Glu Gly Cys Ala Tyr Leu Ser Asp
 115 120 125

25 Asp Gly Ala Ala Thr Ala Arg Cys Tyr Thr Glu Arg Lys Trp Ile Cys
 130 135 140

Arg Lys Arg Ile His
 145

30

<210> 7

<211> 1086

<212> DNA

35 <213> Homo sapiens

<400> 7

ctaaaggtcc cctccccgga gcggagcgca cctaggggtcc ctcttcggtc cccccagccc 60

agctaccggt tcagaccagc agcctcgggg ggcaccccc gccagcctgc ctccctcccg 120

ctcagccctg ccagggttcc ccagccatga atctcttccg attcctggga gacctctccc 180
 acctcctcgc catcatcttg ctactgctca aaatctggaa gtcccgcctg tgcgccggaa 240
 ttccagggaa gagccaggtc ctgtttgctg tgggtgtcac tgcccgatat ctggacctct 300
 tcaccaacta catctcactc tacaacacgt gtatgaaggt ggtctacata gcctgctcct 360
 5 tcaccacggg ctggttgatt tatagcaagt tcaaagctac ttacgatggg aaccatgaca 420
 cgttcagagt ggagttcctg gtcgttccca cagccattct ggcgttcctg gtcaatcatg 480
 acttcacccc tctggagatc ctctggacct tctccatcta cctggagtca gtggccatct 540
 tgccgcagct gttcatgggt agcaagaccg gcgaggcgga gaccatcacc agccactact 600
 tgtttgcgct aggcgtttac cgcacgctct atctcttcaa ctggatctgg cgctaccatt 660
 10 tcgagggtt cttcgacctc atcgccattg tggcaggcct ggtccagaca gtcctctact 720
 gcgatttctt ctacctctat atcaccaaag tcctaaaggg gaagaagttg agtttgccgg 780
 catagccccg gtcctctcca tctctctcct cggcagcagc gggaggcaga ggaaggcggc 840
 agaagatgaa gagctttccc atccagggtt gactttttta agaaccacc tcttgtgctc 900
 cccatcccg ctcctgccgg gtttcagggg gacagtggag gatccaggtc ttggggagct 960
 15 caggacttgg gctgtttgta gttttttgcc ttttagacaa gaaaaaaaaa tctttccact 1020
 ctttagtttt tgattctgat gactcgtttt ttcttctact ctgtggcccc aaattttata 1080-
 aagtga 1086

20 <210> 8

<211> 212

<212> PRT

<213> Homo sapiens

25 <400> 8

Met Asn Leu Phe Arg Phe Leu Gly Asp Leu Ser His Leu Leu Ala Ile
 1 5 10 15

Ile Leu Leu Leu Leu Lys Ile Trp Lys Ser Arg Ser Cys Ala Gly Ile
 30 20 25 30

Ser Gly Lys Ser Gln Val Leu Phe Ala Val Val Phe Thr Ala Arg Tyr
 35 40 45

35 Leu Asp Leu Phe Thr Asn Tyr Ile Ser Leu Tyr Asn Thr Cys Met Lys
 50 55 60

Val Val Tyr Ile Ala Cys Ser Phe Thr Thr Val Trp Leu Ile Tyr Ser
 65 70 75 80

Lys Phe Lys Ala Thr Tyr Asp Gly Asn His Asp Thr Phe Arg Val Glu
 85 90 95
 Phe Leu Val Ile Pro Thr Ala Ile Leu Ala Phe Leu Val Asn His Asp
 5 100 105 110

 Phe Thr Pro Leu Glu Ile Leu Trp Thr Phe Ser Ile Tyr Leu Glu Ser
 115 120 125

 10 Val Ala Ile Leu Pro Gln Leu Phe Met Val Ser Lys Thr Gly Glu Ala
 130 135 140

 Glu Thr Ile Thr Ser His Tyr Leu Phe Ala Leu Gly Val Tyr Arg Thr
 145 150 155 160
 15 Leu Tyr Leu Phe Asn Trp Ile Trp Arg Tyr His Phe Glu Gly Phe Phe
 165 170 175

 Asp Leu Ile Ala Ile Val Ala Gly Leu Val Gln Thr Val Leu Tyr Cys
 20 180 185 190

 Asp Phe Phe Tyr Leu Tyr Ile Thr Lys Val Leu Lys Gly Lys Lys Leu
 195 200 205

 25 Ser Leu Pro Ala
 210

<210> 9

30 <211> 3992

<212> DNA

<213> Homo sapiens

<400> 9

35 ggcttcagga agggcagaca gagtgtccaa aagcgtgaga gcacgaagtg aggagaaggt 60
 ggagaagaga gaagaggaag aggaagagga agagaggaag cggagggaac tgcggccagg 120
 ctaaaagggg aagaagagga tcagcccaag gaggaggaag aggaaaacaa gacaaacagc 180
 cagtgcagag gagaggaacg tgtgtccagt gtcccgatcc ctgcggagct agtagctgag 240
 agctctgtgc cctgggcacc ttgcagccct gcacctgcct gccacttccc caccgaggcc 300

atgggcccag gagttctgct gctcctgctg gtggccacag cttggcatgg tcagggaatc 360
ccagtgatag agcccagtggt ccccgagctg gtcgtgaagc caggagcaac ggtgaccttg 420
cgatgtgtgg gcaatggcag cgtggaatgg gatggccccg catcacctca ctggaccttg 480
tactctgatg gctccagcag catcctcagc accaacaacg ctaccttcca aaacacgggg 540
5 acctatcgct gcactgagcc tggagacccc ctgggaggca gcgccgccat ccacctctat 600
gtcaaagacc ctgcccggcc ctggaacgtg ctagcacagg aggtggctcgt gttcgaggac 660
caggacgcac tactgccctg tctgctcaca gacccggtgc tggaaagcagg cgtctcgtcg 720
gtgctgtgtc gtggccggcc cctcatgctc cacaccaact actccttctc gccctggcat 780
ggcttcacca tccacagggc caagttcatt cagagccagg actatcaatg cagtgccctg 840
10 atgggtggca ggaaggatgat gtccatcagc atccggctga aagtgcagaa agtcatccca 900
gggccccag ccttgacact ggtgcctgca gagctggtgc ggattcgagg ggaggctgcc 960
cagatcgtgt gctcagccag cagcgttgat gttaactttg atgtcttctt ccaacacaac 1020
aacactaagc tcgcaatccc tcaacaatct gactttcata ataaccgtta ccaaaaagtc 1080
ctgacctca acctcgatca agtagatttc caacatgccg gcaactactc ctgctgggcc 1140
15 agcaacgtgc agggcaagca ctccacctcc atgttcttcc gggtaggtaga gagtgcctac 1200
ttgaacttga gctctgagca gaacctcatc caggaggtga ccgtggggga ggggctcaac 1260
ctcaaagtca tggtaggggc ctaccagggc ctgcaagggt ttaactggac ctacctggga 1320
cccttttctg accaccagcc tgagcccaag cttgctaata ctaccaccaa ggacacatac 1380
aggcacacct tcacctctc tctgccccgc ctgaagccct ctgaggctgg ccgctactcc 1440
20 ttctggcca gaaaccagg aggtggaga gctctgacgt ttgagctcac ccttcgatac 1500
ccccagagg taagcgtcat atggacattc atcaacggct ctggcaccct tttgtgtgct 1560
gcctctgggt acccccagcc caacgtgaca tggctgcagt gcagtggcca cactgatagg 1620
tgtgatgagg ccaagtgtc gcaggtctgg gatgacccat accctgaggt cctgagccag 1680
gagcccttcc acaaggtgac ggtgcagagc ctgctgactg ttgagacctt agagcacaac 1740
25 caaacctacg agtgcagggc ccacaacagc gtggggagtg gctcctgggc cttcataccc 1800
atctctgcag gagccacac gcacccccg gatgagttcc tcttcacacc agtgggtgtc 1860
gcctgcatgt ccatcatggc cttgctgctg ctgctgctcc tgctgctatt gtacaagtat 1920
aagcagaagc ccaagtacca ggtccgctgg aagatcatcg agagctatga gggcaacagt 1980
tatactttca tcgacccac gcagctgcct tacaacgaga agtgggagtt ccccggaac 2040
30 aacctgcagt ttgtaagac cctcgagct ggagcctttg ggaagggtgt ggaggccacg 2100
gcctttgtgc tgggcaagga ggatgctgtc ctgaagggtg ctgtgaagat gctgaagtcc 2160
acggcccatg ctgatgagaa ggaggccctc atgtccgagc tgaagatcat gagccacctg 2220
ggccagcacg agaacatcgt caaccttctg ggagcctgta cccatggagg ccctgtactg 2280
gtcatcacgg agtactgttg ctatggcgac ctgctcaact ttctgcaag gaaggctgag 2340
35 gccatgctgg gaccagcct gagccccggc caggaccccc agggaggcgt cgactataag 2400
aacatccacc tcgagaagaa atatgtccgc agggacagtg gcttctccag ccagggtgtg 2460
gacacctatg tggagatgag gcctgtctcc acttcttcaa atgactcctt ctctgagcaa 2520
gacctggaca aggaggatgg acggccctg gagctccggg acctgcttca cttctccagc 2580
caagtagccc agggcatggc cttctctgct tccaagaatt gcatccaccg ggacgtggca 2640

gcgcgtaacg tgctgttgac caatgggtcat gtggccaaga ttggggactt cgggctggct 2700
 agggacatca tgaatgactc caactacatt gtcaagggca atgcccgct gcctgtgaag 2760
 tggatggccc cagagagcat ctttgactgt gtctacacgg ttcagagcga cgtctgggcc 2820
 tatggcatcc tcctctggga gatcttctca cttgggctga atccctaccc tggcatcctg 2880
 5 gtgaacagca agttctataa actggtgaag gatggatacc aaatggccca gcctgcattt 2940
 gcccacaaaga atatatacag catcatgcag gcctgctggg ccttgagacc caccacaga 3000
 cccaccttcc agcagatctg ctccctcctt caggagcagg cccaagagga caggagagag 3060
 cgggactata ccaatctgcc gagcagcagc agaagcgggtg gcagcggcag cagcagcagt 3120
 gagctggagg aggagagctc tagtgagcac ctgacctgct gcgagcaagg ggatatcgcc 3180
 10 cagcccttgc tgcagcccaa caactatcag ttctgctgag gagttgacga caggagtagc 3240
 cactctcccc tcctccaaac ttcaactcct ccatggatgg ggcgacacgg ggagaacata 3300
 caaactctgc cttcggtcat ttactcaac agctcggccc agctctgaaa cttgggaagg 3360
 tgagggattc aggggaggtc agaggatccc acttcctgag catgggccat cactgccagt 3420
 caggggctgg gggctgagcc ctacaccccc gcctcccta ctgttctcat ggtgttgcc 3480
 15 tcgtgtttgc tatgccaact agtagaacct tctttcctaa tccccttate ttcattgaaa 3540
 tggactgact ttatgcctat gaagtcccca ggagctacac tgatactgag aaaaccaggc 3600
 tctttggggc tagacagact ggcagagagt gagatctccc tctctgagag gagcagcaga 3660
 tgctcacaga ccacactcag ctgaggcccc ttggagcagg atggctcctc taagaatctc 3720
 acaggacctc ttagtctctg ccctatacgc cgccttact ccacagcctc acccctccca 3780
 20 ccccatact ggtactgctg taatgagcca agtggcagct aaaagttggg ggtgttctgc 3840
 ccagtcctcg cattctgggc tagaaggcag gggaccttgg cattggctgg ccacaccaag 3900
 caggaagcac aaactcccc aagctgactc atcctaacta acagtcacgc cgtgggatgt 3960
 ctctgtccac attaaactaa cagcattaat gc 3992

25

<210> 10

<211> 972

<212> PRT

<213> Homo sapiens

30

<400> 10

Met Gly Pro Gly Val Leu Leu Leu Leu Leu Val Ala Thr Ala Trp His

1

5

10

15

35 Gly Gln Gly Ile Pro Val Ile Glu Pro Ser Val Pro Glu Leu Val Val

20

25

30

Lys Pro Gly Ala Thr Val Thr Leu Arg Cys Val Gly Asn Gly Ser Val

35

40

45

Tyr Gln Lys Val Leu Thr Leu Asn Leu Asp Gln Val Asp Phe Gln His
 260 265 270

Ala Gly Asn Tyr Ser Cys Val Ala Ser Asn Val Gln Gly Lys His Ser
 5 275 280 285

Thr Ser Met Phe Phe Arg Val Val Glu Ser Ala Tyr Leu Asn Leu Ser
 290 295 300

10 Ser Glu Gln Asn Leu Ile Gln Glu Val Thr Val Gly Glu Gly Leu Asn
 305 310 315 320

Leu Lys Val Met Val Glu Ala Tyr Pro Gly Leu Gln Gly Phe Asn Trp
 325 330 335

15 Thr Tyr Leu Gly Pro Phe Ser Asp His Gln Pro Glu Pro Lys Leu Ala
 340 345 350

Asn Ala Thr Thr Lys Asp Thr Tyr Arg His Thr Phe Thr Leu Ser Leu
 20 355 360 365

Pro Arg Leu Lys Pro Ser Glu Ala Gly Arg Tyr Ser Phe Leu Ala Arg
 370 375 380

25 Asn Pro Gly Gly Trp Arg Ala Leu Thr Phe Glu Leu Thr Leu Arg Tyr
 385 390 395 400

Pro Pro Glu Val Ser Val Ile Trp Thr Phe Ile Asn Gly Ser Gly Thr
 405 410 415

30 Leu Leu Cys Ala Ala Ser Gly Tyr Pro Gln Pro Asn Val Thr Trp Leu
 420 425 430

Gln Cys Ser Gly His Thr Asp Arg Cys Asp Glu Ala Gln Val Leu Gln
 35 435 440 445

Val Trp Asp Asp Pro Tyr Pro Glu Val Leu Ser Gln Glu Pro Phe His
 450 455 460

Lys Val Thr Val Gln Ser Leu Leu Thr Val Glu Thr Leu Glu His Asn
 465 470 475 480

Gln Thr Tyr Glu Cys Arg Ala His Asn Ser Val Gly Ser Gly Ser Trp
 5 485 490 495

Ala Phe Ile Pro Ile Ser Ala Gly Ala His Thr His Pro Pro Asp Glu
 500 505 510

10 Phe Leu Phe Thr Pro Val Val Val Ala Cys Met Ser Ile Met Ala Leu
 515 520 525

Leu Leu Leu Leu Leu Leu Leu Leu Leu Tyr Lys Tyr Lys Gln Lys Pro
 530 535 540

15 Lys Tyr Gln Val Arg Trp Lys Ile Ile Glu Ser Tyr Glu Gly Asn Ser
 545 550 555 560

Tyr Thr Phe Ile Asp Pro Thr Gln Leu Pro Tyr Asn Glu Lys Trp Glu
 20 565 570 575

Phe Pro Arg Asn Asn Leu Gln Phe Gly Lys Thr Leu Gly Ala Gly Ala
 580 585 590

25 Phe Gly Lys Val Val Glu Ala Thr Ala Phe Gly Leu Gly Lys Glu Asp
 595 600 605

Ala Val Leu Lys Val Ala Val Lys Met Leu Lys Ser Thr Ala His Ala
 610 615 620

30 Asp Glu Lys Glu Ala Leu Met Ser Glu Leu Lys Ile Met Ser His Leu
 625 630 635 640

Gly Gln His Glu Asn Ile Val Asn Leu Leu Gly Ala Cys Thr His Gly
 35 645 650 655

Gly Pro Val Leu Val Ile Thr Glu Tyr Cys Cys Tyr Gly Asp Leu Leu
 660 665 670

Asn Phe Leu Arg Arg Lys Ala Glu Ala Met Leu Gly Pro Ser Leu Ser
 675 680 685

Pro Gly Gln Asp Pro Glu Gly Gly Val Asp Tyr Lys Asn Ile His Leu
 5 690 695 700

Glu Lys Lys Tyr Val Arg Arg Asp Ser Gly Phe Ser Ser Gln Gly Val
 705 710 715 720

10 Asp Thr Tyr Val Glu Met Arg Pro Val Ser Thr Ser Ser Asn Asp Ser
 725 730 735

Phe Ser Glu Gln Asp Leu Asp Lys Glu Asp Gly Arg Pro Leu Glu Leu
 740 745 750

15 Arg Asp Leu Leu His Phe Ser Ser Gln Val Ala Gln Gly Met Ala Phe
 755 760 765

Leu Ala Ser Lys Asn Cys Ile His Arg Asp Val Ala Ala Arg Asn Val
 20 770 775 780

Leu Leu Thr Asn Gly His Val Ala Lys Ile Gly Asp Phe Gly Leu Ala
 785 790 795 800

25 Arg Asp Ile Met Asn Asp Ser Asn Tyr Ile Val Lys Gly Asn Ala Arg
 805 810 815

Leu Pro Val Lys Trp Met Ala Pro Glu Ser Ile Phe Asp Cys Val Tyr
 820 825 830

30 Thr Val Gln Ser Asp Val Trp Ser Tyr Gly Ile Leu Leu Trp Glu Ile
 835 840 845

Phe Ser Leu Gly Leu Asn Pro Tyr Pro Gly Ile Leu Val Asn Ser Lys
 35 850 855 860

Phe Tyr Lys Leu Val Lys Asp Gly Tyr Gln Met Ala Gln Pro Ala Phe
 865 870 875 880

Ala Pro Lys Asn Ile Tyr Ser Ile Met Gln Ala Cys Trp Ala Leu Glu
885 890 895

Pro Thr His Arg Pro Thr Phe Gln Gln Ile Cys Ser Phe Leu Gln Glu
5 900 905 910

Gln Ala Gln Glu Asp Arg Arg Glu Arg Asp Tyr Thr Asn Leu Pro Ser
915 920 925

10 Ser Ser Arg Ser Gly Gly Ser Gly Ser Ser Ser Ser Glu Leu Glu Glu
930 935 940

Glu Ser Ser Ser Glu His Leu Thr Cys Cys Glu Gln Gly Asp Ile Ala
945 950 955 960

15 Gln Pro Leu Leu Gln Pro Asn Asn Tyr Gln Phe Cys
965 970

20 <210> 11
<211> 1696
<212> DNA
<213> Homo sapiens

25 <400> 11
ccgagtgtcc acaccctgtg cgtctctctg tcctgccagc actgagggct catccatccg 60
cagagcaggg cagtgggagg agacgccatg acccccatcc tcacggctct gatctgtctc 120
gggctgagtc tgggccccag gaccacgtg caggcagggc acctcccaa gccaccctc 180
tgggctgagc caggctctgt gatcatccag ggaagtcctg tgaccctcag gtgtcagggg 240
30 agccttcagg ctgaggagta ccatctatat agggaaaaca aatcagcatc ctgggttaga 300
cggatacaag agcctgggaa gaatggccag ttcccatcc catccatcac ctgggaacac 360
gcagggcggg atcactgtca gtactacagc cacaatcact catcagagta cagtgacccc 420
ctggagctgg tgggtgacag agcctacagc aaaccacccc tctcagctct gccagccct 480
gtggtgacct taggagggaa cgtgaccctc cagtgtgtct cacaggtggc atttgacggc 540
35 ttcattctgt gtaaggaagg agaagatgaa caccacaac gcctgaactc ccattccat 600
gcccgtaggt ggtcctgggc catcttctcc gtgggccccg tgagcccag tcgcaggtgg 660
tcgtacaggt gctatgctta tgactcgaac tctccctatg tgtggtctct acccagtgat 720
ctcctggagc tctgtgtccc aggtgtttct aagaagccat cactctcagt gcagccaggt 780
cctatggtgg cccctgggga gagcctgacc ctccagtggt tctctgatgt cggctacgac 840

```

agatttggtc tgtataagga gggagaacgt gacttcctcc agcgccctgg ttggcagccc 900
caggctgggc tctcccaggc caacttcacc ctgggccctg tgagcccctc ccacgggggc 960
cagtacagat gctacagtgc acacaacctc tcctccgagt ggtcggcccc cagtgacccc 1020
ctggacatcc tgatcacagg acagttctat gacagaccct ctctctcggg gcagccgggc 1080
5 cccacagtag ccccgagaaa gaacgtgacc ctgctgtgtc agtcacgggg gcagttccac 1140
actttccttc tgaccaagga gggggcaggc catccccac tgcatctgag atcagagcac 1200
caagctcagc agaaccaggc tgaattccgc atgggtcctg tgacctcagc ccacgtgggg 1260
acctacagat gctacagctc actcagctcc aaccctacc tgctgtctct cccagtgac 1320
cccctggagc tcgtgggtctc agcatcccta ggccaacacc cccaggatta cacagtggag 1380
10 aatctcatcc gcatgggtgt ggctggcttg gtctgggtgg tcctcgggat tctgctatct 1440
gaggctcagc acagccagag aagcctacaa gatgcagccg ggaggtgaac agcagagagg 1500
acaatgcata cttcagcgtg gtggagcctc agggacagat ctgatgatcc caggaggctc 1560
tggaggacaa tctaggacct acattatctg gactgtatgc tggtcatttc tagagacagc 1620
aatcaatatt tgagtgtgag gaaactgtct ggggtgattc ctagaagatc attaaactgt 1680
15 ggtacatttt tttgtc 1696

```

<210> 12

20 <211> 466

<212> PRT

<213> Homo sapiens

<400> 12

```

25 Met Thr Pro Ile Leu Thr Val Leu Ile Cys Leu Gly Leu Ser Leu Gly
    1             5             10             15

Pro Arg Thr His Val Gln Ala Gly His Leu Pro Lys Pro Thr Leu Trp
    20             25             30

30 Ala Glu Pro Gly Ser Val Ile Ile Gln Gly Ser Pro Val Thr Leu Arg
    35             40             45

Cys Gln Gly Ser Leu Gln Ala Glu Glu Tyr His Leu Tyr Arg Glu Asn
35     50             55             60

Lys Ser Ala Ser Trp Val Arg Arg Ile Gln Glu Pro Gly Lys Asn Gly
    65             70             75             80

```

Gln Phe Pro Ile Pro Ser Ile Thr Trp Glu His Ala Gly Arg Tyr His
85 90 95

Cys Gln Tyr Tyr Ser His Asn His Ser Ser Glu Tyr Ser Asp Pro Leu
5 100 105 110

Glu Leu Val Val Thr Gly Ala Tyr Ser Lys Pro Thr Leu Ser Ala Leu
115 120 125

10 Pro Ser Pro Val Val Thr Leu Gly Gly Asn Val Thr Leu Gln Cys Val
130 135 140

Ser Gln Val Ala Phe Asp Gly Phe Ile Leu Cys Lys Glu Gly Glu Asp
145 150 155 160

15 Glu His Pro Gln Arg Leu Asn Ser His Ser His Ala Arg Gly Trp Ser
165 170 175

Trp Ala Ile Phe Ser Val Gly Pro Val Ser Pro Ser Arg Arg Trp Ser
20 180 185 190

Tyr Arg Cys Tyr Ala Tyr Asp Ser Asn Ser Pro Tyr Val Trp Ser Leu
195 200 205

25 Pro Ser Asp Leu Leu Glu Leu Leu Val Pro Gly Val Ser Lys Lys Pro
210 215 220

Ser Leu Ser Val Gln Pro Gly Pro Met Val Ala Pro Gly Glu Ser Leu
225 230 235 240

30 Thr Leu Gln Cys Val Ser Asp Val Gly Tyr Asp Arg Phe Val Leu Tyr
245 250 255

Lys Glu Gly Glu Arg Asp Phe Leu Gln Arg Pro Gly Trp Gln Pro Gln
35 260 265 270

Ala Gly Leu Ser Gln Ala Asn Phe Thr Leu Gly Pro Val Ser Pro Ser
275 280 285

His Gly Gly Gln Tyr Arg Cys Tyr Ser Ala His Asn Leu Ser Ser Glu
 290 295 300

Trp Ser Ala Pro Ser Asp Pro Leu Asp Ile Leu Ile Thr Gly Gln Phe
 5 305 310 315 320

Tyr Asp Arg Pro Ser Leu Ser Val Gln Pro Val Pro Thr Val Ala Pro
 325 330 335

10 Gly Lys Asn Val Thr Leu Leu Cys Gln Ser Arg Gly Gln Phe His Thr
 340 345 350

Phe Leu Leu Thr Lys Glu Gly Ala Gly His Pro Pro Leu His Leu Arg
 355 360 365

15 Ser Glu His Gln Ala Gln Gln Asn Gln Ala Glu Phe Arg Met Gly Pro
 370 375 380

Val Thr Ser Ala His Val Gly Thr Tyr Arg Cys Tyr Ser Ser Leu Ser
 20 385 390 395 400

Ser Asn Pro Tyr Leu Leu Ser Leu Pro Ser Asp Pro Leu Glu Leu Val
 405 410 415

25 Val Ser Ala Ser Leu Gly Gln His Pro Gln Asp Tyr Thr Val Glu Asn
 420 425 430

Leu Ile Arg Met Gly Val Ala Gly Leu Val Leu Val Val Leu Gly Ile
 435 440 445

30 Leu Leu Phe Glu Ala Gln His Ser Gln Arg Ser Leu Gln Asp Ala Ala
 450 455 460

Gly Arg
 35 465

<210> 13

<211> 63

<212> DNA

<213> Artificial Sequence

<220>

5 <223> Description of Artificial Sequence: Primer

<400> 13

ggccagtgaa ttgtaatacg actcactata gggaggcggg tttttttttt tttttttttt 60
ttt 63

10

<210> 14

<211> 25

<212> DNA

15 <213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Primer

20 <400> 14

gtcgtcaaga tgctaccggt cagga 25

<210> 15

25 <211> 48

<212> DNA

<213> Artificial Sequence

<220>

30 <223> Description of Artificial Sequence: Primer

<400> 15

ggggacaagt ttgtacaaaa aagcaggcta tggaaaccaa cttctcca 48

35

<210> 16

<211> 53

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Primer

5 <400> 16

ggggaccact ttgtacaaga aagctggggtt cacattgcct gtaactcagt ctc

53

<210> 17

10 <211> 20

<212> DNA

<213> Artificial Sequence

<220>

15 <223> Description of Artificial Sequence: Primer

<400> 17

agcccatagc agatggcaac

20

20

<210> 18

<211> 24

<212> DNA

<213> Artificial Sequence

25

<220>

<223> Description of Artificial Sequence: Primer

<400> 18

30 tgtactttca actttgcatc ctgg

24

<210> 19

<211> 28

35 <212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Primer

<400> 19

aagccaatga caaaccggat aatccctc

28

<210> 20

5 <211> 2051

<212> DNA

<213> Homo sapiens

<400> 20

10 cgccactttg ctggagcatt cactaggcga ggcgctccat cggactcact agccgcactc 60
atgaatcggc accatctgca ggatcacttt ctggaaatag acaagaagaa ctgctgtgtg 120
ttccgagatg acttcattgc caaggtgttg ccgccggtgt tggggctgga gtttatcttt 180
gggcttctgg gcaatggcct tgccctgtgg attttctgtt tccacctcaa gtcctggaaa 240
tccagccgga ttttctgtt caacctggca gtagctgact ttctactgat catctgcctg 300
15 ccgttcgtga tggactacta tgtgcggcgt tcagactgga actttgggga catcccttgc 360
cggtcgtgct tcttcatgtt tgccatgaac cgccagggca gcatcatctt cctcacggtg 420
gtggcggtag acaggtatct ccgggtgggc catccccacc acgccctgaa caagatctcc 480
aattggacag cagccatcat ctcttgccct ctgtggggca tcaactgttg cctaacagtc 540
cacctcctga agaagaagtt gctgatccag aatggccctg caaatgtgtg catcagcttc 600
20 agcatctgcc ataccttccg gtggcacgaa gctatgttcc tcctggagtt cctcctgccc 660
ctgggcatca tcctgttctg ctccagccaga attatctgga gcctgcggca gagacaaatg 720
gaccggcatg ccaagatcaa gagagccatc accttcatca tgggtggggc catcgtcttt 780
gtcatctgct tccttcccag cgtggttgtg cggatccgca tcttctggct cctgcacact 840
tcgggcacgc agaattgtga agtggtaccg tcgggtggacc tggcgttctt tatcactctc 900
25 agcttcacct acatgaacag catgctggac cccgtggtgt actacttctc cagcccatcc 960
tttcccaact tcttctccac ttgatcaac cgctgcctcc agaggaagat gacaggtgag 1020
ccagataata accgcagcac gagcgtcgag ctacacaggg accccaacaa aaccagaggc 1080
gtccagagg cgtaaatggc caactccggt gagccatgga gcccctotta tctggggcca 1140
acctcaaata accattccaa gaaggacat tgtcaccaag aaccagcatc tctggagaaa 1200
30 cagttgggct gttgcatcga gtaatgtcac tggactcggc ctaaggtttc ctggaacttc 1260
cagattcaga gaatctgatt tagggaaact gtggcagatg agtgggagac tggttgcaag 1320
gtgtgaccac aggaatcctg gaggaacaga gagtaaagct tctaggcatc tgaaacttgc 1380
ttcatctctg acgctcgag gactgaagat gggcaaattg taggcgtttc tgctgagcag 1440
agttggagcc agagatctac ttgtgacttg ttggccttct tcccacatct gcctcagact 1500
35 ggggggggct cagctcctcg ggtgatatct agcctgcttg tgagctctag cagggataag 1560
gagagctgag attggaggga attgtgttgc tcctggagga agcccaggca tcattaaaca 1620
agccagtagg tcacctggct tccgtggacc aattcatctt tcagacaagc tttagagaaa 1680
tggtactcagg gaagagactc acatgctttg gttagtatct gtgtttccgg tgggtgtaat 1740
aggggattag cccagaagg gactgagcta aacagtgtta ttatgggaaa ggaaatggca 1800

ttgctgcttt caaccagcga ctaatgcaat ccattcctct cttgtttata gtaatctaag 1860
 ggttgagcag ttaaaacggc ttcaggatag aaagctgttt cccacctgtt tcgttttacc 1920
 attaaaaggg aaacgtgcct ctgccccacg ggtagagggg gtgcacgttc ctctgggttc 1980
 cttcgcttgt gtttctgtac ttaccaaaaa tctaccactt caataaattt tgataggaga 2040
 5 caaaaaaaaa a 2051

<210> 21

<211> 387

10 <212> PRT

<213> Homo sapiens

<400> 21

Met Asn Arg His His Leu Gln Asp His Phe Leu Glu Ile Asp Lys Lys
 15 1 5 10 15

Asn Cys Cys Val Phe Arg Asp Asp Phe Ile Ala Lys Val Leu Pro Pro
 20 25 30

20 Val Leu Gly Leu Glu Phe Ile Phe Gly Leu Leu Gly Asn Gly Leu Ala
 35 40 45

Leu Trp Ile Phe Cys Phe His Leu Lys Ser Trp Lys Ser Ser Arg Ile
 50 55 60

25

Phe Leu Phe Asn Leu Ala Val Ala Asp Phe Leu Leu Ile Ile Cys Leu
 65 70 75 80

Pro Phe Val Met Asp Tyr Tyr Val Arg Arg Ser Asp Trp Asn Phe Gly
 30 85 90 95

Asp Ile Pro Cys Arg Leu Val Leu Phe Met Phe Ala Met Asn Arg Gln
 100 105 110

35 Gly Ser Ile Ile Phe Leu Thr Val Val Ala Val Asp Arg Tyr Phe Arg
 115 120 125

Val Val His Pro His His Ala Leu Asn Lys Ile Ser Asn Trp Thr Ala
 130 135 140

Ala Ile Ile Ser Cys Leu Leu Trp Gly Ile Thr Val Gly Leu Thr Val
 145 150 155 160
 His Leu Leu Lys Lys Lys Leu Leu Ile Gln Asn Gly Pro Ala Asn Val
 5 165 170 175

 Cys Ile Ser Phe Ser Ile Cys His Thr Phe Arg Trp His Glu Ala Met
 180 185 190

 10 Phe Leu Leu Glu Phe Leu Leu Pro Leu Gly Ile Ile Leu Phe Cys Ser
 195 200 205

 Ala Arg Ile Ile Trp Ser Leu Arg Gln Arg Gln Met Asp Arg His Ala
 210 215 220
 15
 Lys Ile Lys Arg Ala Ile Thr Phe Ile Met Val Val Ala Ile Val Phe
 225 230 235 240

 Val Ile Cys Phe Leu Pro Ser Val Val Val Arg Ile Arg Ile Phe Trp
 20 245 250 255

 Leu Leu His Thr Ser Gly Thr Gln Asn Cys Glu Val Tyr Arg Ser Val
 260 265 270

 25 Asp Leu Ala Phe Phe Ile Thr Leu Ser Phe Thr Tyr Met Asn Ser Met
 275 280 285

 Leu Asp Pro Val Val Tyr Tyr Phe Ser Ser Pro Ser Phe Pro Asn Phe
 290 295 300
 30
 Phe Ser Thr Leu Ile Asn Arg Cys Leu Gln Arg Lys Met Thr Gly Glu
 305 310 315 320

 Pro Asp Asn Asn Arg Ser Thr Ser Val Glu Leu Thr Gly Asp Pro Asn
 35 325 330 335

 Lys Thr Arg Gly Ala Pro Glu Ala Leu Met Ala Asn Ser Gly Glu Pro
 340 345 350

Trp Ser Pro Ser Tyr Leu Gly Pro Thr Ser Asn Asn His Ser Lys Lys
355 360 365

Gly His Cys His Gln Glu Pro Ala Ser Leu Glu Lys Gln Leu Gly Cys
5 370 375 380

Cys Ile Glu
385

10

<210> 22
<211> 20
<212> DNA
<213> Artificial Sequence

15

<220>
<223> Description of Artificial Sequence: Primer

<400> 22
20 agcccatagc agatggcaac 20

<210> 23
<211> 24
<212> DNA
25 <213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Primer

30 <400> 23
tgtactttca actttgcatc ctgg 24

<210> 24
<211> 28
35 <212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Primer

<400> 24

aagccaatga caaaccggat aatccctc

28

INTERNATIONAL SEARCH REPORT

Int lional Application No
PCT/EP 01/09727

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 G01N33/50 G01N33/566 C12Q1/68

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 G01N C12Q

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, BIOSIS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X Y	<p>WO 00 31261 A (CADUS PHARMACEUTICAL CORP) 2 June 2000 (2000-06-02)</p> <p>abstract page 47, line 6 -page 48, line 6 page 73, line 7 -page 74, line 10 claims 1,18,41,62,83,103,123,152,171</p> <p style="text-align: center;">--- -/-</p>	<p>1-4,8,9, 24-28, 30-43 5,12-15, 17,18, 21-23, 29,56, 59-61</p>

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the international search

12 November 2001

Date of mailing of the international search report

03/12/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+31-70) 340-3016

Authorized officer

Stricker, J-E

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 01/09727

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 00 06729 A (SLOAN KETTERING INST CANCER) 10 February 2000 (2000-02-10)	1-3,6,7, 24,25, 30,31, 34,35, 38-41 5,29
Y	page 5, line 1 - line 23 page 19, line 25 -page 20, line 6 page 23, line 26 -page 24, line 2 page 25, line 25 -page 26, line 30 claims 1-13,38	
X	VEILLETTE ANDRE ET AL: "High expression of inhibitory receptor SHPS-1 and its association with protein-tyrosine phosphatase SHP-1 in macrophages." JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 273, no. 35, 28 August 1998 (1998-08-28), pages 22719-22728, XP002117548 ISSN: 0021-9258 abstract page 22722, column 2, line 11 -page 22723, column 2, line 6 figures 4,5,7	10,11,16
Y	US 5 639 593 A (KRIEGLER MICHAEL ET AL) 17 June 1997 (1997-06-17) column 1, line 53 - line 61 column 8, line 33 - line 57	5,29
Y	DATABASE BIOSIS 'Online! BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1982 DANIELE R P ET AL: "DEMONSTRATION OF A FORMYL PEPTIDE RECEPTOR ON LUNG MACROPHAGES CORRELATION OF BINDING PROPERTIES WITH CHEMO TAXIS AND RELEASE OF SUPER OXIDE ANION" Database accession no. PREV198376041827 XP002182560 abstract & AMERICAN REVIEW OF RESPIRATORY DISEASE, vol. 126, no. 2, 1982, pages 274-280, ISSN: 0003-0805	12-15, 17,18, 21-23, 56,59-61

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 1-6, 10-15, 19-24, 28, 30-61 (partially)

Present claims 1-6, 10-15, 19-24, 28, 30, 34, 38-40, 44, 45, 49, 53-58 relate to an extremely large number of possible ILM receptors. Support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT is to be found (p.3, 1.30-39), however, for only a reduced number of receptors. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Consequently, the search has been carried out for those parts of the claims which appear to be supported and disclosed, namely those parts relating to the receptors FPRL-1, HM74, AICL, ILT1, SHPS, KDEL and CSF-1.

Present claims 30-61 relate to a substance and its use defined by reference to a desirable characteristic or property, namely an activator or inhibitor of an ILM receptor.

The claims cover all substances having this characteristic or property, whereas the application provides support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT for only a very limited number of such substances. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Independent of the above reasoning, the claims also lack clarity (Article 6 PCT). An attempt is made to define the substances by reference to a result to be achieved. Again, this lack of clarity in the present case is such as to render a meaningful search over the whole of the claimed scope impossible. Consequently, the search has been carried out for those parts of the claims which appear to be clear, supported and disclosed, namely those parts relating to MMK-1, PMA, smoke, LPS, Lipoxin A4, W-peptide, MCP-1.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

Information on patent family members

In tional Application No

PCT/EP 01/09727

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 0031261	A	02-06-2000	AU 2030000 A WO 0031261 A2	13-06-2000 02-06-2000
WO 0006729	A	10-02-2000	US 6160088 A AU 5324599 A EP 1100906 A1 WO 0006729 A1	12-12-2000 21-02-2000 23-05-2001 10-02-2000
US 5639593	A	17-06-1997	US 5545518 A US 5422425 A AT 197646 T AU 8337291 A DE 69132470 D1 EP 0592423 A1 WO 9202822 A1	13-08-1996 06-06-1995 15-12-2000 02-03-1992 21-12-2000 20-04-1994 20-02-1992